valproic acid has been researched along with Abnormalities, Drug-Induced in 368 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Abnormalities, Drug-Induced: Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lamotrigine is used in pregnancy to control epilepsy and mood disorders." | 8.95 | Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis. ( Adams-Webber, T; Barzilay, E; Leibson, T; Nulman, I; Pariente, G; Shulman, T, 2017) |
| "The use of valproic acid in the first trimester of pregnancy is associated with an increased risk of spina bifida, but data on the risks of other congenital malformations are limited." | 8.86 | Valproic acid monotherapy in pregnancy and major congenital malformations. ( Barisic, I; de Jong-van den Berg, LT; Dolk, H; Garne, E; Jentink, J; Loane, MA; Morris, JK, 2010) |
| "Administration of the antiepileptic drug valproic acid (VPA) during early pregnancy can result in a 1-2% incidence of spina bifida aperta, a closure defect of the posterior neural tube in the human." | 8.78 | Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. ( Ehlers, K; Hauck, RS; Nau, H, 1991) |
| "This study, in a meaningful number of exposed pregnancies, confirms a low risk for MCM with levetiracetam monotherapy use in pregnancy." | 7.79 | Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. ( Craig, J; Delanty, N; Hunt, SJ; Irwin, B; Liggan, B; Mawhinney, E; Morrison, PJ; Morrow, J; Parsons, L; Russell, A; Smithson, WH, 2013) |
| "Valproic acid (VPA) is a potent inducer of neural tube defects in human and mouse, its teratogenicity is associated with its potential to generation of free radicals and increase oxidative stress." | 7.78 | Spirulina (arthrospira) protects against valproic acid-induced neural tube defects in mice. ( Chamorro-Cevallos, G; Escalona-Cardoso, GN; Paniagua-Castro, N; Pérez-Pastén, R, 2012) |
| "Health care providers reported lamotrigine exposure during pregnancy, and subsequent outcomes, on a voluntary basis." | 7.77 | Final results from 18 years of the International Lamotrigine Pregnancy Registry. ( Cunnington, MC; Ferber, S; Messenheimer, JA; Tennis, P; Weil, JG; Yerby, M, 2011) |
| "Lamotrigine (LTG) is increasingly being prescribed in pregnancy for women with epilepsy in place of valproate (VPA), because of the teratogenic risks associated with the latter." | 7.76 | Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. ( Eadie, MJ; Graham, JE; Hitchcock, AA; Lander, CM; O'Brien, TJ; Vajda, FJ, 2010) |
| " Maternal treatment with valproic acid (VPA) during pregnancy induces NTD in susceptible fetuses." | 7.73 | Effect of maternal exposure to homocystine on sodium valproate-induced neural tube defects in the mouse embryos. ( Benedict, S; Nagelkerke, N; Padmanabhan, R; Shafiullah, M, 2006) |
| " The mother had been treated with valproic acid (1800mg per day) and lamotrigine (100mg per day) throughout pregnancy." | 7.72 | Valproic acid and lamotrigine treatment during pregnancy. The risk of chromosomal abnormality. ( Cogulu, O; Gunduz, C; Kultursay, N; Ozkinay, F; Yilmaz, D, 2003) |
| " Periconceptional folic acid supplementation is reported to protect embryos from developing neural tube defects (NTD)." | 7.72 | Amelioration of sodium valproate-induced neural tube defects in mouse fetuses by maternal folic acid supplementation during gestation. ( Padmanabhan, R; Shafiullah, MM, 2003) |
| "Valproic acid (VPA) is a known human teratogen." | 6.45 | Valproic acid in pregnancy: how much are we endangering the embryo and fetus? ( Ornoy, A, 2009) |
| "When treatment with valproic acid is the most appropriate treatment to achieve optimal seizure control, a number of measures can be implemented to minimise risk to the fetus." | 6.43 | Valproic acid in epilepsy : pregnancy-related issues. ( Genton, P; Semah, F; Trinka, E, 2006) |
| "Focal epilepsy was diagnosed in 244 (69." | 5.51 | Why do some women with epilepsy use valproic acid despite current guidelines? A single-center cohort study. ( Bosak, M; Słowik, A; Turaj, W, 2019) |
| "Valproic acid (VPA) is a known teratogenic drug." | 5.40 | Middle and inner ear malformations in two siblings exposed to valproic acid during pregnancy: a case report. ( Casselman, J; De Kegel, A; Dhooge, I; Janssens, S; Maes, L; Van Houtte, E, 2014) |
| "Valproic acid (VPA) is an antiepileptic and anti-migraine prophylactic drug." | 5.38 | Valproic acid downregulates RBP4 and elicits hypervitaminosis A-teratogenesis--a kinetic analysis on retinol/retinoic acid homeostatic system. ( Chang, CH; Chen, KC; Chuang, CM; Hsieh, CL; Peng, CC; Peng, RY; Wang, HE, 2012) |
| "PTA significantly reduced VPA-induced exencephaly, while none of the other external malformations such as open eyelid or skeletal malformations such as fused, absent, or bifurcated ribs and fused thoracic vertebrae and fused sternebrae were reduced." | 5.29 | Pantothenic acid decreases valproic acid-induced neural tube defects in mice (I). ( Nagao, T; Sato, M; Shirota, M, 1995) |
| "Fetuses were examined for exencephaly, resorption, and fetal weight retardation on day 18 of gestation." | 5.28 | Methotrexate increases valproic acid-induced developmental toxicity, in particular neural tube defects in mice. ( Elmazar, MM; Nau, H, 1992) |
| "Side effects of carbamazepine (CBZ), valproate (VPA) and clonazepam (CZP) are rare during long-term use but rather common and usually transient during the early phases of treatment." | 5.27 | Side effects of carbamazepine, valproate and clonazepam during long-term treatment of epilepsy. ( Keränen, T; Sivenius, J, 1983) |
| "Lamotrigine is used in pregnancy to control epilepsy and mood disorders." | 4.95 | Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis. ( Adams-Webber, T; Barzilay, E; Leibson, T; Nulman, I; Pariente, G; Shulman, T, 2017) |
| "Valproic acid (VPA) use during pregnancy increases fetal risk of major congenital malformations and cognitive impairment." | 4.93 | Guideline adherence for mentally ill reproductive-aged women on treatment with valproic acid: a retrospective chart review. ( Gotlib, D; Kurlander, J; Muzik, M; Perelstein, E; Riba, M; Zivin, K, 2016) |
| "The use of valproic acid in the first trimester of pregnancy is associated with an increased risk of spina bifida, but data on the risks of other congenital malformations are limited." | 4.86 | Valproic acid monotherapy in pregnancy and major congenital malformations. ( Barisic, I; de Jong-van den Berg, LT; Dolk, H; Garne, E; Jentink, J; Loane, MA; Morris, JK, 2010) |
| "Administration of the antiepileptic drug valproic acid (VPA) during early pregnancy can result in a 1-2% incidence of spina bifida aperta, a closure defect of the posterior neural tube in the human." | 4.78 | Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. ( Ehlers, K; Hauck, RS; Nau, H, 1991) |
| "Valproic acid use during pregnancy results in an absolute risk for spina bifida of 1-2%." | 4.77 | Teratogen update: valproic acid. ( Lammer, EJ; Oakley, GP; Sever, LE, 1987) |
| "We have evaluated 19 children who were exposed to valproic acid (VPA) in utero to look for manifestations of a fetal valproate syndrome (FVS), as proposed by Di Liberti et al." | 4.77 | Verification of the fetal valproate syndrome phenotype. ( Ardinger, HH; Atkin, JF; Blackston, RD; Clarren, SK; Elsas, LJ; Flannery, DB; Harrod, MJ; Lammer, EJ; Livingstone, S; Pellock, JM, 1988) |
| "05) of an increased hazard of fetal malformation associated with exposure to valproate, carbamazepine, topiramate, zonisamide, and with conception after assisted fertilization, but a reduced hazard in the offspring of women who continued to smoke during pregnancy." | 4.31 | Specific fetal malformations following intrauterine exposure to antiseizure medication. ( Eadie, M; Graham, J; Hitchcock, A; Lander, C; O'Brien, T; Perucca, P; Vajda, F, 2023) |
| "Statistical analysis of data from the Raoul Wallenberg Australian Register of Antiepileptic Drugs in Pregnancy involving 2104 folic acid-treated pregnancies in women with epilepsy." | 4.02 | Folic acid dose, valproate, and fetal malformations. ( Eadie, MJ; Graham, JE; Hitchcock, AA; Lander, CM; O'Brien, TJ; Perucca, P; Vajda, FJE, 2021) |
| " Fetal valproate syndrome can be prevented by discontinue of the valproic acid especially during first trimester of pregnancy." | 4.02 | Fetal valproate syndrome with coronary arteriovenous fistula: a case report. ( Baykan, A; Doğan, A; Vural, C, 2021) |
| "There have been several reports of congenital malformations in the offspring of mothers who took valproic acid (VPA) during pregnancy as a treatment for epilepsy." | 3.85 | Fetal Valproate Syndrome. ( Bulut, C; Çaksen, H; Mutlu-Albayrak, H, 2017) |
| "Exposure to alcohol and valproic acid (VPA) during pregnancy can lead to fetal alcohol spectrum disorders and fetal valproate syndrome, respectively." | 3.83 | Effects of developmental alcohol and valproic acid exposure on play behavior of ferrets. ( Filgueiras, CC; Krahe, TE; Medina, AE, 2016) |
| " Here we provide updated results from the UK Epilepsy and Pregnancy Register of the risk of MCMs after monotherapy exposure to valproate, carbamazepine and lamotrigine." | 3.80 | Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. ( Campbell, E; Craig, J; Delanty, N; Hunt, SJ; Irwin, B; Kennedy, F; Liggan, B; Morrison, PJ; Morrow, J; Parsons, L; Russell, A; Smithson, WH, 2014) |
| "Evidence from this and other studies suggests that lamotrigine and levetiracetam have low risk for teratogenesis, but that topiramate exposure early in pregnancy may be associated with dose-related anatomical teratogenesis, as valproate is already known to be." | 3.80 | The teratogenicity of the newer antiepileptic drugs - an update. ( Eadie, MJ; Graham, J; Lander, CM; O'Brien, TJ; Vajda, FJ, 2014) |
| "This study, in a meaningful number of exposed pregnancies, confirms a low risk for MCM with levetiracetam monotherapy use in pregnancy." | 3.79 | Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. ( Craig, J; Delanty, N; Hunt, SJ; Irwin, B; Liggan, B; Mawhinney, E; Morrison, PJ; Morrow, J; Parsons, L; Russell, A; Smithson, WH, 2013) |
| "Based on epidemiological data it is advised to whenever possible avoid valproic acid during pregnancy." | 3.78 | Economic evaluation of anti-epileptic drug therapies with specific focus on teratogenic outcomes. ( Boersma, C; de Jong-van den Berg, LT; Jentink, J; Postma, MJ, 2012) |
| "Valproic acid (VPA) is a potent inducer of neural tube defects in human and mouse, its teratogenicity is associated with its potential to generation of free radicals and increase oxidative stress." | 3.78 | Spirulina (arthrospira) protects against valproic acid-induced neural tube defects in mice. ( Chamorro-Cevallos, G; Escalona-Cardoso, GN; Paniagua-Castro, N; Pérez-Pastén, R, 2012) |
| " Microarray studies in P19 mouse embryocarcinoma cells and mouse embryos have indicated that valproic acid (VPA), an inducer of neural tube defects, deregulates the expression of many genes, including those critically involved in neural tube development." | 3.77 | Short-time gene expression response to valproic acid and valproic acid analogs in mouse embryonic stem cells. ( Dencker, L; Forsberg, M; Gustafson, AL; Jergil, M; Salter, H; Stigson, M; Stockling, K, 2011) |
| "Health care providers reported lamotrigine exposure during pregnancy, and subsequent outcomes, on a voluntary basis." | 3.77 | Final results from 18 years of the International Lamotrigine Pregnancy Registry. ( Cunnington, MC; Ferber, S; Messenheimer, JA; Tennis, P; Weil, JG; Yerby, M, 2011) |
| "Valproic acid, which current guidelines suggest should be avoided in pregnancy, was most notable in terms of strength and breadth of its associations." | 3.77 | Use of antiepileptic medications in pregnancy in relation to risks of birth defects. ( Ahrens, KA; Anderka, MT; Bosco, JL; Gilboa, SM; Holmes, LB; Mitchell, AA; Werler, MM, 2011) |
| "Exposure to the anticonvulsant drug valproic acid (VPA) in utero is associated with a 1-2% increase in neural tube defects (NTDs), however the molecular mechanisms by which VPA induces teratogenesis are unknown." | 3.76 | Epigenetic modifications in valproic acid-induced teratogenesis. ( Tung, EW; Winn, LM, 2010) |
| "Lamotrigine (LTG) is increasingly being prescribed in pregnancy for women with epilepsy in place of valproate (VPA), because of the teratogenic risks associated with the latter." | 3.76 | Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. ( Eadie, MJ; Graham, JE; Hitchcock, AA; Lander, CM; O'Brien, TJ; Vajda, FJ, 2010) |
| " We point out that during the pregnancy 4 of these 5 women with epilepsy had taken valproates, and the other one--carbamazepine." | 3.75 | [Fetal malformations in women with epilepsy]. ( Bozhinov, P; Bozhinova, C; Markova, C, 2009) |
| "(1) Numerous follow-up studies of pregnancies in women with epilepsy show that valproic acid is more teratogenic than other antiepileptics." | 3.75 | Valproic acid: long-term effects on children exposed in utero. ( , 2009) |
| "Valproate (VPA) treatment in pregnancy leads to congenital anomalies, possibly by disrupting folate or homocysteine metabolism." | 3.74 | Valproic acid increases expression of methylenetetrahydrofolate reductase (MTHFR) and induces lower teratogenicity in MTHFR deficiency. ( Gupta, S; Kruger, WD; Leclerc, D; Roy, M; Rozen, R; Wu, Q, 2008) |
| "Although valproic acid (VPA) is used extensively for treating various kinds of epilepsy, it causes hepatotoxicity and teratogenicity." | 3.74 | Tetramethylcyclopropyl analogue of the leading antiepileptic drug, valproic acid: evaluation of the teratogenic effects of its amide derivatives in NMRI mice. ( Bialer, M; Fujiwara, M; Kaufmann, D; Okada, A; Onishi, Y; Shimshoni, JA; Yagen, B, 2008) |
| " By contrast, offspring of rats exposed to carbamazepine (which at the dose used produced low plasma concentrations) or to generalized convulsive seizures showed no clear-cut evidence of dysplasias." | 3.74 | Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias. ( Ben-Ari, Y; Depaulis, A; Jorquera, I; Manent, JB; Mazzucchelli, I; Perucca, E; Represa, A, 2007) |
| "Valproate embryopathy is a well recognized syndrome caused by prenatal exposure to the anticonvulsant valproic acid (Depakote)." | 3.73 | Valproate embryopathy: clinical and cognitive profile in 5 siblings. ( Oppenheimer, SG; Saal, HM; Schorry, EK, 2005) |
| "To determine the rate of occurrence of major malformations in infants whose mothers had taken the drug valproic acid (VPA) as monotherapy during the first trimester of pregnancy and had enrolled in the North American Antiepileptic Drug Pregnancy Registry." | 3.73 | Increased rate of major malformations in offspring exposed to valproate during pregnancy. ( Alsdorf, RM; Holmes, LB; Nambisan, M; Smith, CR; Surve, T; Wyszynski, DF, 2005) |
| "Structure-activity relationship studies of valproic acid (VPA) derivatives have revealed a quantitative correlation between histone deacetylase (HDAC) inhibition and induction of neural tube defects (NTDs) in the NMRI-exencephaly-mouse model, but this correlation has been, so far, limited to congeners with a carboxylic acid function." | 3.73 | S-2-pentyl-4-pentynoic hydroxamic acid and its metabolite s-2-pentyl-4-pentynoic acid in the NMRI-exencephaly-mouse model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further valproic acid hydroxamates an ( Eikel, D; Hoffmann, K; Lampen, A; Nau, H; Zoll, K, 2006) |
| " Maternal treatment with valproic acid (VPA) during pregnancy induces NTD in susceptible fetuses." | 3.73 | Effect of maternal exposure to homocystine on sodium valproate-induced neural tube defects in the mouse embryos. ( Benedict, S; Nagelkerke, N; Padmanabhan, R; Shafiullah, M, 2006) |
| "Valproic acid, a drug commonly used to treat seizures and other psychiatric disorders, causes neural tube defects (NTDs) in exposed fetuses at a rate 20 times higher than in the general population." | 3.73 | Valproic acid-induced fetal malformations are reduced by maternal immune stimulation with granulocyte-macrophage colony-stimulating factor or interferon-gamma. ( Holladay, SD; Hrubec, TC; Salafia, CM; Yan, M; Ye, K, 2006) |
| " The mother had been treated with valproic acid (1800mg per day) and lamotrigine (100mg per day) throughout pregnancy." | 3.72 | Valproic acid and lamotrigine treatment during pregnancy. The risk of chromosomal abnormality. ( Cogulu, O; Gunduz, C; Kultursay, N; Ozkinay, F; Yilmaz, D, 2003) |
| " Periconceptional folic acid supplementation is reported to protect embryos from developing neural tube defects (NTD)." | 3.72 | Amelioration of sodium valproate-induced neural tube defects in mouse fetuses by maternal folic acid supplementation during gestation. ( Padmanabhan, R; Shafiullah, MM, 2003) |
| "In the current study, we wanted to extend our findings and test the hypothesis that Folbp2(-/-) mice are more susceptible to the teratogenic effects of valproic acid (VPA), a commonly used antiepileptic drug that is known to induce neural tube defects (NTDs) in both humans and laboratory animals." | 3.72 | Valproate-induced neural tube defects in folate-binding protein-2 (Folbp2) knockout mice. ( Finnell, RH; Merriweather, MY; Spiegelstein, O; Wicker, NJ, 2003) |
| "We selected all subjects who enrolled in the California Teratogen Information Service (CTIS) pregnancy outcome study for prenatal exposure to carbamazepine or valproic acid between 1990 and 1997 and who received prenatal care through Kaiser Permanente of Southern California (n = 13)." | 3.71 | Selection bias in Teratology Information Service pregnancy outcome studies. ( Chambers, CD; Johnson, KA; Jones, KL; Weber, PA, 2001) |
| "The use of valproic acid during pregnancy has been associated with adverse fetal outcomes, including major and minor congenital malformations, intrauterine growth retardation (IUGR), hyperbilirubinemia, hepatotoxicity, transient hyperglycemia, and fetal and neonatal distress." | 3.71 | Septo-optic dysplasia as a manifestation of valproic acid embryopathy. ( Braddock, SR; McMahon, CL, 2001) |
| "A full-term baby was born to an epileptic mother treated with two anti-epileptic drugs, sodium valproate and phenobarbital, throughout the pregnancy." | 3.70 | [A case of fetal valproate syndrome with intractable wheezing due to submucosal tumor below the vocal cord]. ( Adachi, M; Ai, Y; Maeda, E, 1999) |
| "Clinical and epidemiologic studies have indicated that maternal use of valproic acid during early pregnancy causes an increased risk for spina bifida." | 3.70 | Developmental toxicity of valproic acid during embryonic chick vertebral chondrogenesis. ( Basu, A; Wezeman, FH, 2000) |
| "Teratogenic chemicals (2,3,7, 8-tetrachlorodibenzo-p-dioxin [TCDD], ethyl carbamate [urethane], methylnitrosourea [MNU], or valproic acid [VA]) were given to pregnant mice to induce cleft palate (TCDD, urethane), digital defects (urethane, MNU), or exencephaly (VA)." | 3.70 | Nonspecific stimulation of the maternal immune system. I. Effects On teratogen-induced fetal malformations. ( Blaylock, BL; Gogal, RM; Holladay, SD; Sharova, L; Smith, BJ; Ward, DL, 2000) |
| "We report a newborn with isolated aplasia cutis congenita of the scalp whose mother was treated with valproic acid during pregnancy." | 3.69 | Aplasia cutis congenita of the scalp in an infant exposed to valproic acid in utero. ( Berthier, M; Bonneau, D; Couet, D; Hubert, A; Larrègue, M; Oriot, D, 1994) |
| "Ingestion of the anticonvulsant drug valproic acid and of the angiotensin converting enzyme inhibitor captopril during pregnancy has been associated with abnormal fetal outcome in humans." | 3.69 | Evaluation of the rat embryo culture system as a predictive test for human teratogens. ( Buttar, HS; Guest, I; Smith, S; Varma, DR, 1994) |
| "This experiment was carried out with the aims of comparing the embryotoxic potential of valproic acid (VPA) in rats and mice, better defining the malformation pattern in these species, and comparing the embryotoxic effects detectable in mid-pregnancy to those observed in fetuses at term." | 3.69 | Teratogenic effects of sodium valproate in mice and rats at midgestation and at term. ( Broccia, ML; Giavini, E; Menegola, E; Nau, H; Prati, M; Ricolfi, R, 1996) |
| "Prenatal exposure to the antiepileptic drug valproic acid (VPA) has been associated with the formation of spina bifida aperta, meningocele, and meningomyelocele in the human." | 3.68 | Valproic acid-induced spina bifida: a mouse model. ( Ehlers, K; Merker, HJ; Nau, H; Stürje, H, 1992) |
| " Before 1000 when the ratios of folate metabolites were stable, the rate of valproic acid-induced neural tube defects was reduced from 49% of living fetuses to 12% by coapplication of folinic acid via subcutaneously implanted minipumps." | 3.68 | Diurnal variation of folate concentrations in mouse embryo and plasma: the protective effect of folinic acid on valproic-acid-induced teratogenicity is time dependent. ( Nau, H; Wegner, C, 1991) |
| "The effects of antiepileptic drugs (AED) on infants during pregnancy and delivery were studied in a total of 82 epileptic mothers on various monotherapies; 29 cases receiving valproic acid (VPA), 20 receiving phenytoin (PHT), 18 on carbamazepine (CBZ) and 15 on phenobarbital (PB)." | 3.68 | [Effects of antiepileptic drugs on delivery and early childhood--comparison among mono-therapies of valproic acid, phenytoin, carbamazepine and phenobarbital]. ( Ishikawa, S; Izumi, M; Okada, H; Takeda, A; Tanaka, H, 1991) |
| "An infant with dysmorphic features was born to an epileptic mother who had taken phenytoin and sodium valproate throughout pregnancy." | 3.68 | Neocerebellar hypoplasia in a neonate following intra-uterine exposure to anticonvulsants. ( Hope, PL; Lindenbaum, RH; Squier, W, 1990) |
| "The effect of valproic acid on the distribution of gavaged 65Zn in maternal and embryonic tissue of Sprague-Dawley rats was examined 24 h after gavaging of the drug on d 13 of pregnancy." | 3.67 | The effect of valproic acid on 65Zn distribution in the pregnant rat. ( Hurley, LS; Keen, CL; Peters, JM, 1989) |
| "The association of fetal and neonatal distress, birth measurements, major malformations, and minor anomalies was studied prospectively in 14 infants of women with epilepsy who were receiving valproic acid (VPA) monotherapy and in 12 infants of women with epilepsy who were receiving VPA in combination with other anticonvulsant drugs." | 3.67 | Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. ( Deichl, A; Hartmann, AM; Helge, H; Jäger-Roman, E; Jakob, S; Koch, S; Nau, H; Rating, D; Steldinger, R, 1986) |
| "Four infants who were exposed to sodium valproate or valproic acid during pregnancy are described." | 3.67 | Fetal valproate syndrome: is there a recognisable phenotype? ( Burn, J; Donnai, D; Tucker, SM; Winter, RM, 1987) |
| "Neural tube, craniofacial, and other congenital abnormalities have been described in infants born to mothers with epilepsy who were treated with valproic acid (VPA) during pregnancy." | 3.67 | Congenital abnormalities in two sibs exposed to valproic acid in utero. ( Anderson, L; Chitayat, D; Farrell, K; Hall, JG, 1988) |
| "These patients with refractory generalized epilepsy with sleep-related fast activities do not belong to a well-established syndromic category." | 2.66 | Genetic/idiopathic generalized epilepsies: Not so good as that! ( Crespel, A; Gelisse, P; Nilo, A, 2020) |
| "Valproic acid (VPA) is an anti-epileptic drug (AED) which is currently being investigated for its potential application in the treatment of several types of cancers, including solid and non-solid tumor." | 2.58 | Teratology of valproic acid: an updated review of the possible mediating mechanisms. ( Ponzano, A; Tiboni, GM, 2018) |
| "Valproic acid (VPA) is a known human teratogen." | 2.45 | Valproic acid in pregnancy: how much are we endangering the embryo and fetus? ( Ornoy, A, 2009) |
| "When treatment with valproic acid is the most appropriate treatment to achieve optimal seizure control, a number of measures can be implemented to minimise risk to the fetus." | 2.43 | Valproic acid in epilepsy : pregnancy-related issues. ( Genton, P; Semah, F; Trinka, E, 2006) |
| " If a dosage of AEDs in pregnant women with epilepsy is reduced to a reasonable minimum and the monotherapy is preferred, the risk of congenital malformations in their offspring can be minimized." | 2.42 | [Effect of anti-epileptic drugs on human placenta and the fetus]. ( Semczuk, M; Semczuk-Sikora, A, 2004) |
| "Neural tube defects were seen in 3% of the sample." | 2.41 | Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature. ( Kozma, C, 2001) |
| "Valproic acid is an anticonvulsant that has been associated with open neural tube defects." | 2.38 | Valproic acid prenatal exposure. Association with lipomyelomeningocele. ( Carter, BS; Stewart, JM, 1989) |
| "Valproic acid has probable teratogenic potential in humans but the number of reported cases is few and the spectrum of anomalies is broad so it is not possible to delineate a definite fetal valproate syndrome." | 2.37 | Congenital malformations associated with maternal use of valproic acid. ( Gauthier, M; Huot, C; Larbrisseau, A; Lebel, M, 1987) |
| " We investigated potential transgenerational adverse effects of valproate." | 1.72 | Transgenerational adverse effects of valproate? A patient report from 90 affected families. ( Bewley, S; Braillon, A; Hill, C; MacLennan, AH; Martin, M, 2022) |
| "Corneal dermoids may regress spontaneously." | 1.72 | Spontaneous Partial Regression of Bilateral Grade III Corneal Dermoids Associated With Fetal Valproate Spectrum Disorder. ( Colak, D; Kiratli, H; Koç, İ, 2022) |
| " However, women must balance the benefit of treatment against all possible adverse effects." | 1.62 | Active Surveillance of the Safety of Medications Used During Pregnancy. ( Bateman, BT; Hernández-Díaz, S; Huybrechts, KF; Kulldorff, M; Mogun, H; Wang, SV; Zhu, Y, 2021) |
| "For the determination of acute toxicity of chemicals in zebrafish (Danio rerio) embryos, the OECD test guideline 236, relative to the Fish Embryo Toxicity Test (FET), stipulates a dose-response analysis of four lethal core endpoints and a quantitative characterization of abnormalities including their time-dependency." | 1.62 | Multistate models of developmental toxicity: Application to valproic acid-induced malformations in the zebrafish embryo. ( Beaudouin, R; Bois, FY; Braunbeck, T; Brotzmann, K; Siméon, S, 2021) |
| "Logistic regression analysis showed that maternal age over 31 years, family histories of fetal malformation, and conception after assisted fertility treatment, and also dosage of valproate, carbamazepine, and topiramate, made statistically significant (P<0." | 1.62 | The contribution of non-drug factors to fetal malformation in anti-seizure-medication-treated pregnancy. ( Eadie, MJ; Graham, JE; Hitchcock, AA; Lander, CM; O'Brien, TJ; Vajda, FJE, 2021) |
| "Valproic acid (VPA) is an effective anti-epileptic drug clinically used to treat seizures, bipolar disorders and neuropathic pain in women of reproductive age." | 1.62 | Characterizing the effects of in utero valproic acid exposure on murine fetoplacental development. ( Shafique, S; Winn, LM, 2021) |
| "Prepregnancy reduction in VPA dosage reduced the hazard of fetal malformations, whereas ceasing intake of the drug decreased the hazard to one similar to that which applies in the general population, but at a cost of decreased control of epileptic seizures during the pregnancies studied." | 1.56 | Pregnancy after valproate withdrawal-Fetal malformations and seizure control. ( Eadie, MJ; Graham, JE; Hitchcock, AA; Lander, CM; O'Brien, TJ; Vajda, FJE, 2020) |
| "Significant decreases in pregnancy weight gain and the number of live fetuses were observed when VPA was administered at the high dose, whereas the percentage of exencephalic fetuses was significantly increased in VPA treated compared with an equivalent VCD dosage group." | 1.51 | Teratogenicity of valproic acid and its constitutional isomer, amide derivative valnoctamide in mice. ( Bialer, M; Cabrera, RM; Finnell, RH; Lin, YL; Wlodarczyk, BJ, 2019) |
| "Focal epilepsy was diagnosed in 244 (69." | 1.51 | Why do some women with epilepsy use valproic acid despite current guidelines? A single-center cohort study. ( Bosak, M; Słowik, A; Turaj, W, 2019) |
| " While women younger than 50 years of age were less likely to be prescribed valproate than men in the same age group, and at a lower dosage, it is unclear to what extent this reflects clinicians' concerns about teratogenicity or is driven by perceptions of the indication for valproate, and the dosage required, for the treatment of different phases of the disorder in men and women." | 1.48 | A UK clinical audit addressing the quality of prescribing of sodium valproate for bipolar disorder in women of childbearing age. ( Barnes, TRE; Bhatti, S; Cookson, J; Fagan, E; Ferrier, IN; Paton, C, 2018) |
| "Evidence for the comparative teratogenic risk of antiepileptic drugs is insufficient, particularly in relation to the dosage used." | 1.48 | Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. ( Battino, D; Bonizzoni, E; Craig, J; Lindhout, D; Perucca, E; Sabers, A; Thomas, SV; Tomson, T; Vajda, F, 2018) |
| "The treatment profile for epilepsy, seizure control, and maternal and neonatal outcomes in both groups were compared using Chi-square test or Fisher's exact test and Mann-Whitney U test." | 1.40 | Impact of planning of pregnancy in women with epilepsy on seizure control during pregnancy and on maternal and neonatal outcomes. ( Abe, K; Hamada, H; Minakami, H; Obata-Yasuoka, M; Yamada, T; Yoshikawa, H, 2014) |
| "Valproic acid (VPA) is a commonly prescribed drug for those affected by epilepsy and bipolar disorders." | 1.40 | Brief report novel mechanism for valproate-induced teratogenicity. ( Fathe, K; Finnell, RH; Palacios, A, 2014) |
| "Valproic acid (VPA) is a known teratogenic drug." | 1.40 | Middle and inner ear malformations in two siblings exposed to valproic acid during pregnancy: a case report. ( Casselman, J; De Kegel, A; Dhooge, I; Janssens, S; Maes, L; Van Houtte, E, 2014) |
| " The overall mean maternal valproate dosage taken by women in the Register decreased over the last 5 years of the study period." | 1.39 | Dose dependence of fetal malformations associated with valproate. ( Eadie, MJ; Graham, JE; Lander, CM; O'Brien, TJ; Vajda, FJ, 2013) |
| " The mean dosage of AED for valproate was 498 mg/day and carbamazepine was 555 mg/day." | 1.39 | Malformation in index pregnancy in women with epilepsy is not followed by recurrence in subsequent pregnancy. ( Begum, S; Sarma, SP; Thomas, SV, 2013) |
| " Neurologists had progressively prescribed valproate less frequently and in lower dosage than other classes of practitioner over the 10-year study period, with a parallel decrease in occurrence of fetal malformations in pregnancies referred to the Register." | 1.38 | The prescribing of antiepileptic drugs for pregnant Australian women. ( Eadie, MJ; Graham, J; Hitchcock, AA; Hollingworth, S; Horgan, D; Lander, CM; O'Brien, TJ; Roten, A; Vajda, FJ, 2012) |
| "Valproate exposed embryos have microcephaly and disrupted cardiovasculature with delayed vessel circulation, thrombus formation, and slow heart rate." | 1.38 | Valproate-induced teratogenesis in Japanese rice fish (Oryzias latipes) embryogenesis. ( Dasmahapatra, AK; Khan, IA; Wu, M, 2012) |
| "Valproic acid (VPA) is an antiepileptic and anti-migraine prophylactic drug." | 1.38 | Valproic acid downregulates RBP4 and elicits hypervitaminosis A-teratogenesis--a kinetic analysis on retinol/retinoic acid homeostatic system. ( Chang, CH; Chen, KC; Chuang, CM; Hsieh, CL; Peng, CC; Peng, RY; Wang, HE, 2012) |
| "Valproic acid (VPA) is a teratogenic drug used in pregnant women for the treatment of epilepsy and mood disorders." | 1.37 | Severe fetal valproate syndrome: combination of complex cardiac defect, multicystic dysplastic kidney, and trigonocephaly. ( Cetinkaya, M; Köksal, N; Ozkan, H; Yapici, S, 2011) |
| " dosed on day 8 with VPA 400mg/kg or TSA (16 mg/kg)." | 1.36 | VPA-related axial skeletal defects and apoptosis: a proposed event cascade. ( Broccia, ML; Di Renzo, F; Giavini, E; Menegola, E, 2010) |
| "Our cases were spina bifida registrations and all other malformed registrations (excluding folic acid sensitive malformations) were used as controls." | 1.36 | Does folic acid use decrease the risk for spina bifida after in utero exposure to valproic acid? ( Bakker, MK; de Jong-van den Berg, LT; Jentink, J; Nijenhuis, CM; Wilffert, B, 2010) |
| " Comparative pharmacokinetic analysis showed that α-Cl-TMCD is less susceptible to liver first-pass effect than α-F-TMCD because of lower total (metabolic) clearance and liver extraction ratio." | 1.36 | Comparative pharmacodynamic and pharmacokinetic analysis of two anticonvulsant halo derivatives of 2,2,3,3-tetramethylcyclopropanecarboxamide, an amide of a cyclic analog of valproic acid. ( Bialer, M; Finnell, RH; Hen, N; Kaufmann, D; Pessah, N; Wlodarczyk, B; Yagen, B, 2010) |
| "Valproic acid (VPA) is a major antiepileptic drug (AED); however, its use is limited by two life-threatening side effects: teratogenicity and hepatotoxicity." | 1.34 | Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid. ( Bialer, M; Finnell, RH; Shimshoni, JA; Wlodarczyk, B; Yagen, B, 2007) |
| " It showed a beneficial pharmacokinetic profile in rats, having a high oral bioavailability of 75% and satisfactory values of clearance and volume of distribution." | 1.34 | Anticonvulsant activity, neural tube defect induction, mutagenicity and pharmacokinetics of a new potent antiepileptic drug, N-methoxy-2,2,3,3-tetramethylcyclopropane carboxamide. ( Bialer, M; Finnell, RH; Lamb, JG; Sobol, E; White, HS; Wlodarczyk, BJ; Yagen, B, 2007) |
| " The concordance is apparent both by en masse correlation of fold-changes and by detailed similarity of dose-response profiles of individual genes." | 1.33 | Association of valproate-induced teratogenesis with histone deacetylase inhibition in vivo. ( Berman, MG; Gentleman, RC; Green, JB; Gurvich, N; Klein, PS; Wittner, BS, 2005) |
| " Unlike the situation for the other drugs, the malformation rate in those exposed to valproate increased with increasing maternal drug dosage (P<0." | 1.33 | Maternal valproate dosage and foetal malformations. ( Eadie, MJ; Vajda, FJ, 2005) |
| " No tolerance was evident in the intravenous pentylenetetrazol test after twice-daily dosing of ABT-769 (0." | 1.33 | Preclinical profiling and safety studies of ABT-769: a compound with potential for broad-spectrum antiepileptic activity. ( Bennani, Y; Bitner, RS; Chemburkar, SR; Chen, J; Curzon, P; Dart, MJ; Decker, MW; Durmuller, N; Fox, GB; Giardina, WJ; Grayson, GK; Harris, RR; Hui, JY; Jolly, R; Komater, VA; Ku, Y; Lockwood, M; Marsh, KC; Miner, HM; Nikkel, AL; Pan, JB; Pu, YM; Radek, RJ; Roux, S; Sullivan, JP; Wang, L; Waring, JF, 2005) |
| "Valproic acid (VPA) is a widely used anticonvulsant medication with well-known teratogenic effects in both humans and in experimental animal model systems." | 1.33 | Valproic acid-induced skeletal malformations: associated gene expression cascades. ( Cabrera, RM; Finnell, RH; Giavini, E; Massa, V; Menegola, E, 2005) |
| "Valproic acid (VPA) is an anticonvulsant drug that is widely used therapeutically for a variety of neurological conditions." | 1.33 | Myo-inositol enhances teratogenicity of valproic acid in the mouse. ( Finnell, RH; Giavini, E; Massa, V; Wlodarczyk, B, 2006) |
| "Women with epilepsy have a higher risk of having dysmorphic child." | 1.33 | A case of fetal anticonvulsant syndrome with severe bilateral upper limb defect. ( Batukan, C; Ceylaner, G; Ceylaner, S; Guven, MA; Uzel, M, 2006) |
| "4% in the high dosage groups." | 1.32 | Chemically induced supernumerary lumbar ribs in CD-1 mice: size distribution and dose response. ( Branch, S; Chernoff, N; Rogers, JM; Setzer, RW, 2004) |
| "Significant increases in fetal loss and exencephaly rate were observed with VPA at 800 mg/kg compared to the vehicle control." | 1.32 | Amidic modification of valproic acid reduces skeletal teratogenicity in mice. ( Aoki, Y; Bialer, M; Fujiwara, M; Kurihara, H; Okada, A, 2004) |
| "Valproic acid (VPA) is an effective antiepileptic medication, the use of which in females of childbearing age is complicated by its ability to induce birth defects, including neural tube defects (NTDs), in exposed embryos." | 1.32 | Teratogenicity of valproate conjugates with anticonvulsant activity in mice. ( Alexander, G; Chatterjie, N; Finnell, RH; Spiegelstein, O, 2003) |
| "Valproic acid (VPA) is an antiepileptic drug used clinically." | 1.32 | Effect of valproic acid on fetal and maternal organs in the mouse: a morphological study. ( Emmanouil-Nikoloussi, EN; Foroglou, NG; Kerameos-Foroglou, CH; Thliveris, JA, 2004) |
| " Although SNR incidence generally increased with increasing dose of RA, a strict dose-response relationship was lacking." | 1.32 | Experimental studies on cervical and lumbar ribs in mouse embryos. ( Padmanabhan, RR; Rengasamy, P, 2004) |
| "Metopic craniosynostosis may be an adverse effect of valproic acid exposed fetus." | 1.31 | [Metopic craniosynostosis, probable effect of intrauterine exposure to maternal valproate treatment]. ( Bensouda, B; Bruel, H; Chabrolle, JP; Degre, S; Ickowicz, V; Poinsot, J; Simon, A, 2001) |
| " On the other hand, the peak concentration and duration of exposure to valproic acid and ethylhexanoic acid were very similar despite a more severe teratologic outcome following valproic acid, which indicated higher intrinsic activity of this latter agent." | 1.29 | Pharmacokinetic determinants of embryotoxicity in rats associated with organic acids. ( Collins, MD; Nau, H; Scott, WJ, 1994) |
| "PTA significantly reduced VPA-induced exencephaly, while none of the other external malformations such as open eyelid or skeletal malformations such as fused, absent, or bifurcated ribs and fused thoracic vertebrae and fused sternebrae were reduced." | 1.29 | Pantothenic acid decreases valproic acid-induced neural tube defects in mice (I). ( Nagao, T; Sato, M; Shirota, M, 1995) |
| "Fetuses were examined for exencephaly, resorption, and fetal weight retardation on day 18 of gestation." | 1.28 | Methotrexate increases valproic acid-induced developmental toxicity, in particular neural tube defects in mice. ( Elmazar, MM; Nau, H, 1992) |
| "Over the past 10 years, knowledge gained about the pharmacokinetic profiles of valproate and carbamazepine has increased the clinical effectiveness of their use." | 1.28 | Pharmacokinetics of valproate and carbamazepine. ( Wilder, BJ, 1992) |
| "Carbamazepine was the antiepileptic drug prescribed most frequently followed by valproic acid." | 1.28 | [The course of pregnancy and teratogenicity of antiepileptic agents in 66 patients with epilepsy]. ( Bülau, P; Fröscher, W; Herrmann, R; Hildenbrand, G; Niesen, M; Penin, H, 1991) |
| "The joint toxic action of three binary mixtures was determined for the embryo malformation endpoint of the aquatic FETAX (frog embryo teratogenesis assay: Xenopus) test system." | 1.28 | Initial evaluation of developmental malformation as an end point in mixture toxicity hazard assessment for aquatic vertebrates. ( Dawson, DA; Wilke, TS, 1991) |
| " Nulliparous female CD-1 mice were dosed intraperitoneally on day 8 of gestation with 340 mg/kg of sodium valproate." | 1.28 | Teratogenic effects on the neuroepithelium of the CD-1 mouse embryo exposed in utero to sodium valproate. ( De Philip, RM; Paulson, RB; Sucheston, ME; Turner, S, 1990) |
| "The rate of neural tube defects (exencephaly) produced by the S-enantiomer was about 4 times higher than that produced by the R-enantiomer." | 1.28 | Asymmetric synthesis and enantioselective teratogenicity of 2-n-propyl-4-pentenoic acid (4-en-VPA), an active metabolite of the anticonvulsant drug, valproic acid. ( Hauck, RS; Nau, H, 1989) |
| "Side effects of carbamazepine (CBZ), valproate (VPA) and clonazepam (CZP) are rare during long-term use but rather common and usually transient during the early phases of treatment." | 1.27 | Side effects of carbamazepine, valproate and clonazepam during long-term treatment of epilepsy. ( Keränen, T; Sivenius, J, 1983) |
| "The objective of this investigation was to study the teratogenic effects of dosage levels and time of administration of three anticonvulsant drugs (carbamazepine [CMZ], sodium valproate [NaV], and diphenylhydantoin [DPH]) on craniofacial development in the CD-1 mouse fetus." | 1.27 | Teratogenic effects of dosage levels and time of administration of carbamazepine, sodium valproate, and diphenylhydantoin on craniofacial development in the CD-1 mouse fetus. ( Eluma, FO; Hayes, TG; Paulson, RB; Sucheston, ME, 1984) |
| " Maternal pharmacokinetic parameters and plasma metabolites were determined for VPA on the first and last day of dosing for the 10X dose group." | 1.27 | Predicting the human teratogenic potential of the anticonvulsant, valproic acid, from a non-human primate model. ( Cukierski, MA; Hendrickx, AG; Mast, TJ; Nau, H, 1986) |
| " This result has to be taken into account when dose-response relationships are evaluated." | 1.27 | Pharmacokinetic aspects of drug effects in vitro: effects of serum protein binding on concentration and teratogenicity of valproic acid and 2-en-valproic acid in whole embryos in culture. ( Klug, S; Lewandowski, C; Nau, H; Neubert, D, 1986) |
| "Interspecies differences in regard to the teratogenicity of drugs can be the result of differing pharmacokinetic processes that determine the crucial concentration-time relationships in the embryo." | 1.27 | Species differences in pharmacokinetics and drug teratogenesis. ( Nau, H, 1986) |
| "Valproic acid, which is an isomer of 2-EXHA, also produced similar defects, and was approximately twice as potent as 2-EHXA." | 1.27 | Teratogenicity of di(2-ethylhexyl) phthalate, 2-ethylhexanol, 2-ethylhexanoic acid, and valproic acid, and potentiation by caffeine. ( Randall, JL; Ritter, EJ; Ritter, JM; Scott, WJ, 1987) |
| " The VPA-400 dose was maternally toxic in as much as maternal weight gain was reduced, but no deaths occurred." | 1.27 | Teratogenicity and developmental toxicity of valproic acid in rats. ( Vorhees, CV, 1987) |
| " There was no significant change in pharmacokinetic parameters (maternal plasma elimination rate, area under the curve, peak plasma concentration) between the first and last days of treatment at either dose level." | 1.27 | Valproic acid developmental toxicity and pharmacokinetics in the rhesus monkey: an interspecies comparison. ( Binkerd, P; Cukierski, MA; Cukierski, MJ; Hendrickx, AG; Nau, H; Rowland, JM; Rowland, JR, 1988) |
| " The incidence of malformations was greater at the higher dosage levels of 340 mg/kg and 560 mg/kg, with a predominance of exencephaly, open eyelids, and gross skeletal defects." | 1.27 | Teratogenic effects of valproate in the CD-1 mouse fetus. ( Hayes, TG; Paulson, GW; Paulson, RB; Sucheston, ME, 1985) |
| "Spina Bifida, Congenital Heart Defects, Clefts, Diaphragmatic Hernia and Trisomy 18 were more frequent than expected among babies with maternal epilepsy." | 1.27 | Maternal epilepsy and birth defects: a case-control study in the Italian Multicentric Registry of Birth Defects (IPIMC). ( Bertollini, R; Mastroiacovo, P; Segni, G, 1985) |
| "The incidence of malformations in fetal mice exposed to phenytoin depends on drug dosage and the strain of mice." | 1.26 | Teratogenic effects of anticonvulsants. ( Paulson, GW; Paulson, RB, 1981) |
| " VPA was excreted in the neonates with a mean half-life of 47 +/- 15 hr (n = 8) which is approximately 4 times the mean value found in adult epileptics." | 1.26 | Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother's milk and clinical status in neonates of epileptic mothers. ( Häuser, I; Helge, H; Koch, S; Nau, H; Rating, D, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 80 (21.74) | 18.7374 |
| 1990's | 67 (18.21) | 18.2507 |
| 2000's | 103 (27.99) | 29.6817 |
| 2010's | 92 (25.00) | 24.3611 |
| 2020's | 26 (7.07) | 2.80 |
| Authors | Studies |
|---|---|
| Shimshoni, JA | 3 |
| Bialer, M | 12 |
| Wlodarczyk, B | 5 |
| Finnell, RH | 12 |
| Yagen, B | 8 |
| Pessah, N | 2 |
| Martin, M | 1 |
| Hill, C | 1 |
| Bewley, S | 1 |
| MacLennan, AH | 1 |
| Braillon, A | 1 |
| Battistoni, M | 1 |
| Bacchetta, R | 1 |
| Di Renzo, F | 4 |
| Metruccio, F | 1 |
| Moretto, A | 1 |
| Menegola, E | 6 |
| Błaszczyk, B | 1 |
| Miziak, B | 1 |
| Pluta, R | 1 |
| Czuczwar, SJ | 1 |
| Kalim, A | 1 |
| Reardon, W | 2 |
| Gruppuso, PA | 1 |
| Ahmed, R | 1 |
| Adashi, EY | 1 |
| Kiratli, H | 1 |
| Colak, D | 1 |
| Koç, İ | 1 |
| Cohen, JM | 3 |
| Alvestad, S | 3 |
| Cesta, CE | 3 |
| Bjørk, MH | 3 |
| Leinonen, MK | 3 |
| Nørgaard, M | 3 |
| Einarsdóttir, K | 3 |
| Engeland, A | 3 |
| Gissler, M | 3 |
| Karlstad, Ø | 3 |
| Klungsøyr, K | 3 |
| Odsbu, I | 3 |
| Reutfors, J | 3 |
| Selmer, RM | 3 |
| Tomson, T | 11 |
| Ulrichsen, SP | 3 |
| Zoega, H | 3 |
| Furu, K | 3 |
| Manière-Guerrero, I | 1 |
| Bonizzoni, E | 4 |
| Battino, D | 7 |
| Clinard, F | 1 |
| Mathieu-Huart, A | 1 |
| Perucca, E | 8 |
| Pouzaud, F | 1 |
| Thomas, SV | 5 |
| Vajda, F | 7 |
| Rousselle, C | 1 |
| O'Brien, T | 3 |
| Graham, J | 12 |
| Hitchcock, A | 4 |
| Perucca, P | 2 |
| Lander, C | 3 |
| Eadie, M | 2 |
| Jackson, A | 2 |
| Ward, H | 1 |
| Bromley, RL | 1 |
| Deshpande, C | 1 |
| Vasudevan, P | 1 |
| Scurr, I | 1 |
| Dean, J | 1 |
| Shannon, N | 1 |
| Berg, J | 1 |
| Holder, S | 1 |
| Baralle, D | 1 |
| Clayton-Smith, J | 7 |
| Gandhi, M | 1 |
| Rac, MWF | 1 |
| McKinney, J | 1 |
| Suri, R | 1 |
| Socol, DK | 1 |
| Gitlin, M | 1 |
| Vajda, FJE | 7 |
| O'Brien, TJ | 18 |
| Graham, JE | 6 |
| Hitchcock, AA | 7 |
| Lander, CM | 14 |
| Eadie, MJ | 17 |
| Jazayeri, D | 2 |
| Braine, E | 1 |
| McDonald, S | 1 |
| Dworkin, S | 1 |
| Powell, KL | 1 |
| Griggs, K | 1 |
| Jones, NC | 1 |
| Nilo, A | 1 |
| Gelisse, P | 1 |
| Crespel, A | 1 |
| Shafique, S | 2 |
| Winn, LM | 3 |
| Goldspink, R | 1 |
| Pumipi, T | 1 |
| Dey, S | 1 |
| Menkes, DB | 1 |
| Haskell, H | 1 |
| Huybrechts, KF | 1 |
| Kulldorff, M | 1 |
| Hernández-Díaz, S | 1 |
| Bateman, BT | 1 |
| Zhu, Y | 1 |
| Mogun, H | 1 |
| Wang, SV | 1 |
| Doğan, A | 1 |
| Baykan, A | 1 |
| Vural, C | 1 |
| Siméon, S | 1 |
| Beaudouin, R | 1 |
| Brotzmann, K | 1 |
| Braunbeck, T | 1 |
| Bois, FY | 1 |
| Seshachala, BB | 1 |
| Jose, M | 1 |
| Lathikakumari, AM | 1 |
| Murali, S | 1 |
| Kumar, AS | 1 |
| Hughes, JE | 1 |
| Buckley, N | 1 |
| Looney, Y | 1 |
| Kirwan, G | 1 |
| Curran, S | 1 |
| Doherty, CP | 1 |
| Mullooly, M | 1 |
| Bennett, KE | 1 |
| Ajinkya, S | 1 |
| Fox, J | 1 |
| Lekoubou, A | 1 |
| Ponzano, A | 2 |
| Tiboni, GM | 2 |
| Pariente, G | 1 |
| Leibson, T | 1 |
| Shulman, T | 1 |
| Adams-Webber, T | 1 |
| Barzilay, E | 1 |
| Nulman, I | 2 |
| Stadelmaier, R | 1 |
| Nasri, H | 1 |
| Deutsch, CK | 1 |
| Bauman, M | 1 |
| Hunt, A | 1 |
| Stodgell, CJ | 1 |
| Adams, J | 1 |
| Holmes, LB | 5 |
| Casassus, B | 2 |
| Gotlib, D | 2 |
| Ramaswamy, R | 1 |
| Kurlander, JE | 1 |
| DeRiggi, A | 1 |
| Riba, M | 3 |
| Wise, J | 1 |
| Ivanova, EA | 1 |
| Kapitsa, IG | 1 |
| Zolotov, NN | 1 |
| Pozdnev, VF | 1 |
| Voronina, TA | 1 |
| Wiedemann, K | 1 |
| Stüber, T | 1 |
| Rehn, M | 1 |
| Frieauff, E | 1 |
| Kirihata, Y | 1 |
| Ban, Y | 1 |
| Nakamori, C | 1 |
| Takagi, H | 1 |
| Hashimoto, T | 1 |
| Tsutsumi, S | 1 |
| Mohd Yunos, H | 1 |
| Green, A | 1 |
| Paton, C | 2 |
| Cookson, J | 1 |
| Ferrier, IN | 1 |
| Bhatti, S | 1 |
| Fagan, E | 1 |
| Barnes, TRE | 1 |
| Angus-Leppan, H | 2 |
| Liu, RSN | 1 |
| Wieck, A | 1 |
| Jones, S | 1 |
| Craig, J | 7 |
| Lindhout, D | 7 |
| Sabers, A | 4 |
| Macfarlane, A | 1 |
| Greenhalgh, T | 1 |
| Ornoy, A | 3 |
| Koren, G | 3 |
| Yanai, J | 1 |
| Kälviäinen, R | 1 |
| Straus, S | 1 |
| Dogne, JM | 1 |
| Bakchine, S | 1 |
| Haas, M | 1 |
| Arora, V | 1 |
| Joshi, A | 1 |
| Lall, M | 1 |
| Agarwal, S | 1 |
| Bijarnia Mahay, S | 1 |
| Dua Puri, R | 1 |
| Chander Verma, I | 1 |
| Lin, YL | 1 |
| Cabrera, RM | 2 |
| Wlodarczyk, BJ | 2 |
| Heneghan, C | 1 |
| Aronson, JK | 1 |
| Perera, C | 1 |
| Patterson, S | 1 |
| Bruxner, G | 1 |
| Watkins, LV | 1 |
| Cock, HR | 1 |
| Shankar, R | 1 |
| Bosak, M | 1 |
| Słowik, A | 1 |
| Turaj, W | 1 |
| Vajda, FJ | 11 |
| Miller, MW | 1 |
| Church, CC | 1 |
| Jacob, J | 1 |
| Ribes, V | 1 |
| Moore, S | 1 |
| Constable, SC | 1 |
| Sasai, N | 1 |
| Gerety, SS | 1 |
| Martin, DJ | 1 |
| Sergeant, CP | 1 |
| Wilkinson, DG | 1 |
| Briscoe, J | 1 |
| Begum, S | 1 |
| Sarma, SP | 1 |
| Abe, K | 1 |
| Hamada, H | 1 |
| Yamada, T | 1 |
| Obata-Yasuoka, M | 1 |
| Minakami, H | 1 |
| Yoshikawa, H | 1 |
| Shah, KH | 1 |
| Shailaja, S | 1 |
| Girisha, KM | 1 |
| Onishi, E | 1 |
| Ishii, H | 1 |
| Sasaki, C | 1 |
| Campbell, E | 1 |
| Kennedy, F | 1 |
| Russell, A | 3 |
| Smithson, WH | 2 |
| Parsons, L | 3 |
| Morrison, PJ | 2 |
| Liggan, B | 3 |
| Irwin, B | 3 |
| Delanty, N | 3 |
| Hunt, SJ | 2 |
| Morrow, J | 4 |
| Veiby, G | 2 |
| Daltveit, AK | 2 |
| Engelsen, BA | 2 |
| Gilhus, NE | 2 |
| Hsieh, CL | 2 |
| Chen, KC | 2 |
| Lin, PX | 1 |
| Peng, CC | 2 |
| Peng, RY | 2 |
| Nakken, KO | 1 |
| Taubøll, E | 2 |
| Fryer, A | 3 |
| Clowes, V | 1 |
| Fathe, K | 1 |
| Palacios, A | 1 |
| Van Houtte, E | 1 |
| Casselman, J | 1 |
| Janssens, S | 1 |
| De Kegel, A | 1 |
| Maes, L | 1 |
| Dhooge, I | 1 |
| Sargar, KM | 1 |
| Herman, TE | 1 |
| Siegel, MJ | 1 |
| Tanoshima, M | 1 |
| Kobayashi, T | 1 |
| Tanoshima, R | 1 |
| Beyene, J | 1 |
| Ito, S | 1 |
| Arman, D | 1 |
| Sancak, S | 1 |
| Topcuoglu, S | 1 |
| Karatekin, G | 1 |
| Balon, R | 1 |
| Perelstein, E | 1 |
| Kurlander, J | 1 |
| Zivin, K | 1 |
| Muzik, M | 1 |
| Krahe, TE | 1 |
| Filgueiras, CC | 1 |
| Medina, AE | 1 |
| Mutlu-Albayrak, H | 1 |
| Bulut, C | 1 |
| Çaksen, H | 1 |
| Kikuchi, N | 1 |
| Ohira, S | 1 |
| Asaka, R | 1 |
| Tanaka, K | 1 |
| Takatsu, A | 1 |
| Shiozawa, T | 1 |
| Wen, X | 1 |
| Hartzema, A | 1 |
| Delaney, JA | 1 |
| Brumback, B | 1 |
| Liu, X | 1 |
| Egerman, R | 1 |
| Roth, J | 1 |
| Segal, R | 1 |
| Meador, KJ | 5 |
| Semmler, A | 1 |
| Frisch, C | 2 |
| Bleul, C | 1 |
| Smith, D | 1 |
| Bigler, L | 1 |
| Prost, JC | 1 |
| Blom, H | 1 |
| Linnebank, M | 1 |
| Bromfield, EB | 1 |
| Dworetzky, BA | 1 |
| Wyszynski, DF | 3 |
| Smith, CR | 2 |
| Baldwin, EJ | 1 |
| Roy, M | 1 |
| Leclerc, D | 1 |
| Wu, Q | 1 |
| Gupta, S | 1 |
| Kruger, WD | 1 |
| Rozen, R | 1 |
| Okada, A | 6 |
| Onishi, Y | 2 |
| Kaufmann, D | 2 |
| Fujiwara, M | 6 |
| Whitehall, J | 1 |
| Smith, J | 1 |
| Kluger, BM | 1 |
| Harden, CL | 3 |
| Sethi, NK | 1 |
| Cole, RL | 1 |
| Van Ross, ER | 1 |
| Larsen, K | 1 |
| Blichfeldt, S | 1 |
| Sahlholdt, L | 1 |
| Rasmussen, JO | 1 |
| Ackers, R | 1 |
| Besag, FM | 1 |
| Wade, A | 1 |
| Murray, ML | 1 |
| Wong, IC | 1 |
| Hüsch, K | 1 |
| Angenstein, F | 1 |
| Kudin, A | 1 |
| Kunz, W | 1 |
| Elger, CE | 1 |
| Helmstaedter, C | 1 |
| Pennell, PB | 3 |
| Hauser, WA | 2 |
| Gronseth, GS | 2 |
| French, JA | 2 |
| Wiebe, S | 2 |
| Thurman, D | 2 |
| Koppel, BS | 2 |
| Kaplan, PW | 2 |
| Robinson, JN | 2 |
| Hopp, J | 2 |
| Ting, TY | 2 |
| Gidal, B | 2 |
| Hovinga, CA | 2 |
| Wilner, AN | 2 |
| Vazquez, B | 2 |
| Holmes, L | 2 |
| Krumholz, A | 2 |
| Finnell, R | 2 |
| Hirtz, D | 2 |
| Le Guen, C | 2 |
| Bozhinov, P | 1 |
| Bozhinova, C | 1 |
| Markova, C | 1 |
| Martínez-Frías, ML | 3 |
| Somerville, ER | 1 |
| Cook, MJ | 1 |
| Trivedi, A | 1 |
| Halliday, R | 1 |
| Waters, K | 1 |
| Levison, J | 1 |
| Noyori, H | 1 |
| Broccia, ML | 4 |
| Giavini, E | 6 |
| Downing, C | 1 |
| Biers, J | 1 |
| Larson, C | 1 |
| Kimball, A | 1 |
| Wright, H | 1 |
| Ishii, T | 1 |
| Gilliam, D | 1 |
| Johnson, T | 1 |
| Schmitz, B | 1 |
| Dennig, D | 1 |
| Rating, D | 5 |
| Steinhoff, BJ | 1 |
| Mayer, T | 1 |
| Jentink, J | 3 |
| Loane, MA | 1 |
| Dolk, H | 1 |
| Barisic, I | 1 |
| Garne, E | 1 |
| Morris, JK | 1 |
| de Jong-van den Berg, LT | 3 |
| Bakker, MK | 1 |
| Nijenhuis, CM | 1 |
| Wilffert, B | 1 |
| Tung, EW | 1 |
| Hen, N | 1 |
| Dyer, C | 1 |
| de Jong, E | 1 |
| Doedée, AM | 1 |
| Reis-Fernandes, MA | 1 |
| Nau, H | 24 |
| Piersma, AH | 1 |
| Ozkan, H | 1 |
| Cetinkaya, M | 1 |
| Köksal, N | 1 |
| Yapici, S | 1 |
| Jergil, M | 1 |
| Forsberg, M | 1 |
| Salter, H | 1 |
| Stockling, K | 1 |
| Gustafson, AL | 1 |
| Dencker, L | 1 |
| Stigson, M | 1 |
| Cunnington, MC | 1 |
| Weil, JG | 1 |
| Messenheimer, JA | 1 |
| Ferber, S | 1 |
| Yerby, M | 1 |
| Tennis, P | 1 |
| Kulaga, S | 1 |
| Sheehy, O | 1 |
| Zargarzadeh, AH | 1 |
| Moussally, K | 1 |
| Bérard, A | 1 |
| Horgan, D | 1 |
| Hollingworth, S | 1 |
| Roten, A | 2 |
| Walcott, EC | 1 |
| Higgins, EA | 1 |
| Desai, NS | 1 |
| Werler, MM | 1 |
| Ahrens, KA | 1 |
| Bosco, JL | 1 |
| Mitchell, AA | 1 |
| Anderka, MT | 1 |
| Gilboa, SM | 1 |
| Cowden, J | 1 |
| Padnos, B | 1 |
| Hunter, D | 1 |
| MacPhail, R | 1 |
| Jensen, K | 1 |
| Padilla, S | 1 |
| Wu, M | 1 |
| Khan, IA | 1 |
| Dasmahapatra, AK | 1 |
| Mawhinney, E | 2 |
| Campbell, J | 1 |
| Smithson, W | 1 |
| Robertson, I | 1 |
| Morrison, P | 2 |
| Hunt, S | 1 |
| Boersma, C | 1 |
| Postma, MJ | 1 |
| Sarkar, S | 1 |
| Sardar, SK | 1 |
| Munian, D | 1 |
| Bhattacharya, S | 1 |
| Majhi, B | 1 |
| Balmer, NV | 1 |
| Weng, MK | 1 |
| Zimmer, B | 1 |
| Ivanova, VN | 1 |
| Chambers, SM | 1 |
| Nikolaeva, E | 1 |
| Jagtap, S | 1 |
| Sachinidis, A | 1 |
| Hescheler, J | 1 |
| Waldmann, T | 1 |
| Leist, M | 1 |
| Chuang, CM | 1 |
| Chang, CH | 1 |
| Wang, HE | 1 |
| Kozhokaru, AB | 1 |
| Karlov, VA | 2 |
| Zhidkova, IA | 1 |
| Serkina, AV | 1 |
| Escalona-Cardoso, GN | 1 |
| Paniagua-Castro, N | 1 |
| Pérez-Pastén, R | 1 |
| Chamorro-Cevallos, G | 1 |
| Koo, J | 1 |
| Zavras, A | 1 |
| Malm, H | 1 |
| Kajantie, E | 1 |
| Kivirikko, S | 1 |
| Kääriäinen, H | 1 |
| Peippo, M | 1 |
| Somer, M | 1 |
| Witters, I | 1 |
| Van Assche, F | 1 |
| Fryns, JP | 1 |
| Mawer, G | 3 |
| Coyle, H | 2 |
| Kini, U | 3 |
| Ozkinay, F | 1 |
| Cogulu, O | 1 |
| Gunduz, C | 1 |
| Yilmaz, D | 1 |
| Kultursay, N | 1 |
| Kaaja, E | 1 |
| Kaaja, R | 1 |
| Hiilesmaa, V | 1 |
| Padmanabhan, R | 2 |
| Shafiullah, MM | 1 |
| Hornby, SJ | 1 |
| Welham, RA | 1 |
| Biernacki, B | 2 |
| Minta, M | 2 |
| Zmudzki, J | 1 |
| Anoop, P | 1 |
| Sasidharan, CK | 1 |
| Semczuk-Sikora, A | 2 |
| Rogowska, W | 1 |
| Semczuk, M | 2 |
| Gjerstad, L | 1 |
| Henriksen, T | 1 |
| Husby, H | 1 |
| Kawanishi, CY | 1 |
| Hartig, P | 1 |
| Bobseine, KL | 1 |
| Schmid, J | 1 |
| Cardon, M | 1 |
| Massenburg, G | 1 |
| Chernoff, N | 2 |
| Duchowny, M | 1 |
| Spiegelstein, O | 2 |
| Merriweather, MY | 1 |
| Wicker, NJ | 1 |
| Rogers, JM | 2 |
| Setzer, RW | 1 |
| Branch, S | 1 |
| Kurihara, H | 2 |
| Aoki, Y | 4 |
| Chatterjie, N | 1 |
| Alexander, G | 1 |
| Emmanouil-Nikoloussi, EN | 1 |
| Foroglou, NG | 1 |
| Kerameos-Foroglou, CH | 1 |
| Thliveris, JA | 1 |
| Rengasamy, P | 1 |
| Padmanabhan, RR | 1 |
| Shorvon, SD | 1 |
| Adab, N | 2 |
| Vinten, J | 2 |
| Ayres, J | 1 |
| Baker, G | 1 |
| Gorry, J | 1 |
| Gregg, J | 1 |
| Nicolaides, P | 1 |
| Pickering, L | 1 |
| Tunnicliffe, L | 1 |
| Chadwick, DW | 1 |
| Solinas, C | 1 |
| Cook, M | 2 |
| Kushima, K | 2 |
| Schorry, EK | 1 |
| Oppenheimer, SG | 1 |
| Saal, HM | 1 |
| de Oliveira, RS | 1 |
| Lajeunie, E | 1 |
| Arnaud, E | 1 |
| Greensmith, A | 1 |
| Renier, D | 1 |
| Penovich, P | 1 |
| Gaily, E | 1 |
| Nambisan, M | 1 |
| Surve, T | 1 |
| Alsdorf, RM | 1 |
| Alsdorf, R | 1 |
| Gurvich, N | 1 |
| Berman, MG | 1 |
| Wittner, BS | 1 |
| Gentleman, RC | 1 |
| Klein, PS | 1 |
| Green, JB | 1 |
| Artama, M | 1 |
| Auvinen, A | 1 |
| Raudaskoski, T | 1 |
| Isojärvi, I | 1 |
| Isojärvi, J | 2 |
| Giardina, WJ | 1 |
| Dart, MJ | 1 |
| Harris, RR | 1 |
| Bitner, RS | 1 |
| Radek, RJ | 1 |
| Fox, GB | 1 |
| Chemburkar, SR | 1 |
| Marsh, KC | 1 |
| Waring, JF | 1 |
| Hui, JY | 1 |
| Chen, J | 1 |
| Curzon, P | 1 |
| Grayson, GK | 1 |
| Komater, VA | 1 |
| Ku, Y | 1 |
| Lockwood, M | 1 |
| Miner, HM | 1 |
| Nikkel, AL | 1 |
| Pan, JB | 1 |
| Pu, YM | 1 |
| Wang, L | 1 |
| Bennani, Y | 1 |
| Durmuller, N | 1 |
| Jolly, R | 1 |
| Roux, S | 1 |
| Sullivan, JP | 1 |
| Decker, MW | 1 |
| Prudenziati, M | 1 |
| Minucci, S | 1 |
| Massa, V | 3 |
| Eikel, D | 1 |
| Hoffmann, K | 1 |
| Zoll, K | 1 |
| Lampen, A | 1 |
| Genton, P | 2 |
| Semah, F | 1 |
| Trinka, E | 1 |
| Nava-Ocampo, AA | 1 |
| Moretti, ME | 1 |
| Sussman, R | 1 |
| Guven, MA | 1 |
| Batukan, C | 1 |
| Ceylaner, S | 1 |
| Ceylaner, G | 1 |
| Uzel, M | 1 |
| Shafiullah, M | 1 |
| Benedict, S | 1 |
| Nagelkerke, N | 1 |
| Sobol, E | 2 |
| Baker, GA | 1 |
| Kalayjian, LA | 1 |
| Liporace, JD | 1 |
| Loring, DW | 1 |
| Smith, JC | 1 |
| Wolff, MC | 1 |
| Lamb, JG | 1 |
| White, HS | 1 |
| Hrubec, TC | 1 |
| Yan, M | 1 |
| Ye, K | 1 |
| Salafia, CM | 1 |
| Holladay, SD | 2 |
| Chakravarty, A | 1 |
| Mukherjee, A | 1 |
| Roy, D | 1 |
| Cappelletti, G | 1 |
| Manent, JB | 1 |
| Jorquera, I | 1 |
| Mazzucchelli, I | 1 |
| Depaulis, A | 1 |
| Ben-Ari, Y | 1 |
| Represa, A | 1 |
| Carrim, ZI | 1 |
| McKay, L | 1 |
| Sidiki, SS | 1 |
| Lavy, TE | 1 |
| James, L | 1 |
| Barnes, TR | 1 |
| Lelliott, P | 1 |
| Taylor, D | 1 |
| Diav-Citrin, O | 1 |
| Shechtman, S | 1 |
| Bar-Oz, B | 1 |
| Cantrell, D | 1 |
| Arnon, J | 1 |
| Brown, NA | 3 |
| Kao, J | 1 |
| Fabro, S | 1 |
| Hurd, RW | 1 |
| Wilder, BJ | 2 |
| Van Rinsvelt, HA | 1 |
| Robert, E | 5 |
| Rosa, F | 1 |
| Meinardi, H | 3 |
| Löfkvist, E | 1 |
| Mauguiere, F | 1 |
| Bailey, CJ | 1 |
| Pool, RW | 1 |
| Poskitt, EM | 1 |
| Harris, F | 1 |
| Löscher, W | 1 |
| Koch, S | 4 |
| Göpfert-Geyer, I | 1 |
| Jäger-Roman, E | 3 |
| Jakob, S | 2 |
| Huth, H | 1 |
| Hartmann, A | 1 |
| Helge, H | 4 |
| Frew, J | 1 |
| ten Kate, LP | 1 |
| Swagemakers, ML | 1 |
| Weemhoff, RA | 1 |
| van Eck, JH | 1 |
| Leck, I | 1 |
| Cordero, JF | 1 |
| Oakley, GP | 2 |
| Friis, ML | 1 |
| Fukuda, T | 1 |
| Fukushima, Y | 2 |
| Kuroki, Y | 1 |
| Robert, JM | 1 |
| Lapras, C | 1 |
| Keränen, T | 1 |
| Sivenius, J | 1 |
| Jeavons, PM | 1 |
| Loiseau, P | 2 |
| Bantz, EW | 1 |
| Eluma, FO | 1 |
| Sucheston, ME | 3 |
| Hayes, TG | 2 |
| Paulson, RB | 4 |
| Philbert, A | 2 |
| Pedersen, B | 1 |
| Niermeijer, MF | 1 |
| Dalens, B | 1 |
| Raynaud, EJ | 1 |
| Gaulme, J | 1 |
| Paulson, GW | 2 |
| Gomez, MR | 1 |
| Clay, SA | 1 |
| McVie, R | 1 |
| Chen, H | 1 |
| Häuser, I | 1 |
| Dam, M | 1 |
| Pedersen, A | 1 |
| Laegreid, L | 1 |
| Kyllerman, M | 1 |
| Hedner, T | 1 |
| Hagberg, B | 1 |
| Viggedahl, G | 1 |
| Scott, WJ | 4 |
| Collins, MD | 3 |
| Okada, T | 1 |
| Tomoda, T | 1 |
| Hisakawa, H | 1 |
| Kurashige, T | 1 |
| Yerby, MS | 3 |
| Oakeshott, P | 1 |
| Hunt, G | 1 |
| Hubert, A | 1 |
| Bonneau, D | 1 |
| Couet, D | 1 |
| Berthier, M | 1 |
| Oriot, D | 1 |
| Larrègue, M | 1 |
| Guest, I | 1 |
| Buttar, HS | 1 |
| Smith, S | 1 |
| Varma, DR | 1 |
| Ylagan, LR | 1 |
| Budorick, NE | 1 |
| Aulthouse, AL | 1 |
| Hitt, DC | 1 |
| Martin, PJ | 1 |
| Millac, PA | 1 |
| Kaneko, S | 1 |
| Otani, K | 1 |
| Kondo, T | 1 |
| Kan, R | 1 |
| Takeda, A | 2 |
| Nakane, Y | 1 |
| Sharony, R | 1 |
| Garber, A | 1 |
| Viskochil, D | 1 |
| Schreck, R | 1 |
| Platt, LD | 1 |
| Ward, R | 1 |
| Buehler, BA | 1 |
| Graham, JM | 1 |
| Lorenzo Sanz, G | 1 |
| Serna Saugar, C | 1 |
| Quintana Castilla, A | 1 |
| Lozano Giménez, C | 1 |
| Aparicio Meix, JM | 1 |
| Donnai, D | 2 |
| Sato, M | 1 |
| Shirota, M | 1 |
| Nagao, T | 1 |
| Park, BK | 1 |
| Pirmohamed, M | 1 |
| Kitteringham, NR | 1 |
| Prati, M | 1 |
| Ricolfi, R | 1 |
| Barnes, GL | 1 |
| Mariani, BD | 1 |
| Tuan, RS | 1 |
| Espinasse, M | 1 |
| Manouvrier, S | 1 |
| Boute, O | 1 |
| Farriaux, JP | 1 |
| Krätke, R | 1 |
| Kirschbaum, F | 2 |
| Ubeda, N | 1 |
| Alonso, E | 1 |
| Martín-Rodríguez, JC | 1 |
| Varela-Moreiras, G | 1 |
| Puerta, J | 1 |
| Pérez-Miguelsanz, J | 1 |
| Johnson, EM | 1 |
| Courage-Maguire, C | 1 |
| Bacon, CL | 1 |
| Regan, CM | 1 |
| Chabrolle, JP | 2 |
| Poinsot, J | 2 |
| Bruel, H | 2 |
| Amussini, P | 1 |
| Hall, JL | 1 |
| Harris, MJ | 1 |
| Juriloff, DM | 1 |
| Andrews, JE | 1 |
| Ebron-McCoy, MT | 1 |
| Bojic, U | 1 |
| Kavlock, RJ | 1 |
| Radatz, M | 1 |
| Ehlers, K | 3 |
| Tueth, MJ | 1 |
| Murphy, TK | 1 |
| Evans, DL | 1 |
| Bradaï, R | 1 |
| Hishida, R | 1 |
| Mo, CN | 1 |
| Ladusans, EJ | 1 |
| Prieto, L | 1 |
| Patterson, V | 1 |
| Canger, R | 1 |
| Canevini, MP | 1 |
| Fumarola, C | 1 |
| Guidolin, L | 1 |
| Vignoli, A | 1 |
| Mamoli, D | 1 |
| Palmieri, C | 1 |
| Molteni, F | 1 |
| Granata, T | 1 |
| Hassibi, P | 1 |
| Zamperini, P | 1 |
| Pardi, G | 1 |
| Avanzini, G | 1 |
| Adachi, M | 1 |
| Ai, Y | 1 |
| Maeda, E | 1 |
| Faiella, A | 1 |
| Wernig, M | 1 |
| Consalez, GG | 1 |
| Hostick, U | 1 |
| Hofmann, C | 1 |
| Hustert, E | 1 |
| Boncinelli, E | 1 |
| Balling, R | 1 |
| Nadeau, JH | 1 |
| Gigantelli, JW | 1 |
| Braddock, SR | 2 |
| Johnson, LN | 1 |
| Pandya, NA | 1 |
| Jani, BR | 1 |
| Moore, SJ | 2 |
| Turnpenny, P | 1 |
| Quinn, A | 1 |
| Glover, S | 1 |
| Lloyd, DJ | 1 |
| Montgomery, T | 1 |
| Dean, JC | 2 |
| Basu, A | 1 |
| Wezeman, FH | 1 |
| Fairgrieve, SD | 1 |
| Jackson, M | 1 |
| Jonas, P | 1 |
| Walshaw, D | 1 |
| White, K | 1 |
| Montgomery, TL | 1 |
| Burn, J | 2 |
| Lynch, SA | 1 |
| Sonoda, T | 2 |
| Sharova, L | 1 |
| Smith, BJ | 1 |
| Gogal, RM | 1 |
| Ward, DL | 1 |
| Blaylock, BL | 1 |
| Kozma, C | 1 |
| Iqbal, MM | 1 |
| Gundlapalli, SP | 1 |
| Ryan, WG | 1 |
| Ryals, T | 1 |
| Passman, TE | 1 |
| Harvey, EA | 1 |
| Coull, BA | 1 |
| Huntington, KB | 1 |
| Khoshbin, S | 1 |
| Hayes, AM | 1 |
| Ryan, LM | 1 |
| Gardner, RJ | 1 |
| Savarirayan, R | 1 |
| Dunne, KB | 1 |
| McLellan, JA | 1 |
| Coleman, LT | 1 |
| Suthers, GK | 1 |
| Johnson, KA | 1 |
| Weber, PA | 1 |
| Jones, KL | 1 |
| Chambers, CD | 1 |
| McMahon, CL | 1 |
| Nagai, T | 1 |
| Sodhi, P | 1 |
| Poddar, B | 1 |
| Parmar, V | 1 |
| Bescoby-Chambers, N | 1 |
| Forster, P | 1 |
| Bates, G | 1 |
| Waes, JG | 1 |
| Eudy, JD | 1 |
| Rosenquist, TH | 1 |
| Bensouda, B | 1 |
| Simon, A | 1 |
| Ickowicz, V | 1 |
| Degre, S | 1 |
| Włodarczyk, B | 1 |
| Glover, SJ | 1 |
| Quinn, AG | 1 |
| Barter, P | 1 |
| Hart, J | 1 |
| Turnpenny, PD | 1 |
| Conomy, JP | 1 |
| Elmazar, MM | 2 |
| Oberemm, A | 1 |
| Almuna, R | 1 |
| Tohá, D | 1 |
| Campos, G | 1 |
| del Río, S | 1 |
| Stürje, H | 1 |
| Merker, HJ | 1 |
| Buntinx, IM | 1 |
| Siemes, H | 1 |
| Leavitt, A | 1 |
| Erickson, DM | 1 |
| McCormick, KB | 1 |
| Loewenson, RB | 1 |
| Sells, CJ | 1 |
| Benedetti, TJ | 1 |
| Dravet, C | 1 |
| Julian, C | 1 |
| Legras, C | 1 |
| Magaudda, A | 1 |
| Guerrini, R | 1 |
| Soulayrol, S | 1 |
| Giraud, N | 1 |
| Mesdjian, E | 1 |
| Trentin, G | 1 |
| Meijer, JW | 1 |
| Thiel, R | 1 |
| Dawson, DA | 3 |
| Fröscher, W | 1 |
| Herrmann, R | 1 |
| Niesen, M | 1 |
| Bülau, P | 1 |
| Penin, H | 1 |
| Hildenbrand, G | 1 |
| Hauck, RS | 2 |
| Walling, KM | 1 |
| Resnick, E | 1 |
| Wegner, C | 1 |
| Tanaka, H | 1 |
| Izumi, M | 1 |
| Okada, H | 1 |
| Ishikawa, S | 1 |
| Palea, KM | 1 |
| Mallet, EC | 1 |
| Elana, G | 1 |
| Bataille, H | 1 |
| Parlier, G | 1 |
| Wilke, TS | 1 |
| Cohen, LS | 1 |
| Heller, VL | 1 |
| Verloes, A | 1 |
| Frikiche, A | 1 |
| Gremillet, C | 1 |
| Paquay, T | 1 |
| Decortis, T | 1 |
| Rigo, J | 1 |
| Senterre, J | 1 |
| Fradkin, R | 1 |
| Turner, S | 1 |
| De Philip, RM | 1 |
| Squier, W | 1 |
| Hope, PL | 1 |
| Lindenbaum, RH | 1 |
| Vanfleteren, M | 1 |
| Crolla, D | 1 |
| Vermeulen, J | 1 |
| Devos, E | 1 |
| Minematsu, S | 1 |
| Taki, M | 1 |
| Watanabe, M | 1 |
| Takahashi, M | 1 |
| Wakui, Y | 1 |
| Ishihara, K | 1 |
| Takeda, S | 1 |
| Fujii, Y | 1 |
| Ohdo, S | 1 |
| Ohba, K | 1 |
| Okishima, T | 1 |
| Hayakawa, K | 1 |
| Carter, BS | 1 |
| Stewart, JM | 1 |
| Robinek, F | 1 |
| Czeizel, E | 1 |
| Keen, CL | 1 |
| Peters, JM | 1 |
| Hurley, LS | 1 |
| Haddad, J | 1 |
| Messer, J | 1 |
| Willard, D | 1 |
| Serville, F | 1 |
| Carles, D | 1 |
| Guibaud, S | 1 |
| Dallay, D | 1 |
| Chadwick, D | 1 |
| Chevallier, B | 1 |
| Nègre, V | 1 |
| Bidat, E | 1 |
| Lagardère, B | 1 |
| Piccione, E | 1 |
| Ticconi, C | 1 |
| Cennamo, M | 1 |
| Staunton, H | 1 |
| Kerr, BM | 1 |
| Levy, RH | 1 |
| Pacifici, GM | 1 |
| Bertilsson, L | 1 |
| Rane, A | 1 |
| Gram, L | 1 |
| Bentsen, KD | 1 |
| Coakley, ME | 1 |
| Mast, TJ | 1 |
| Cukierski, MA | 2 |
| Hendrickx, AG | 2 |
| Deichl, A | 1 |
| Hartmann, AM | 1 |
| Steldinger, R | 1 |
| Chessa, L | 1 |
| Iannetti, P | 1 |
| Lewandowski, C | 2 |
| Klug, S | 2 |
| Neubert, D | 2 |
| Wallace, SJ | 1 |
| Petrere, JA | 1 |
| Anderson, JA | 1 |
| Sakowski, R | 1 |
| Fitzgerald, JE | 1 |
| de la Iglesia, FA | 1 |
| Durá, T | 1 |
| Moya, M | 1 |
| Muñoz, M | 1 |
| Juste, M | 1 |
| Castaño, C | 1 |
| Blankenburg, G | 1 |
| Chahoud, I | 1 |
| Franz, G | 1 |
| Herken, R | 1 |
| Kastner, M | 1 |
| Kröger, J | 1 |
| Krowke, R | 1 |
| Ritter, EJ | 1 |
| Randall, JL | 1 |
| Ritter, JM | 1 |
| Khoury, MJ | 1 |
| Holtzman, NA | 1 |
| Vorhees, CV | 1 |
| Bertollini, R | 2 |
| Källen, B | 1 |
| Mastroiacovo, P | 2 |
| Lammer, EJ | 2 |
| Sever, LE | 1 |
| Huot, C | 1 |
| Gauthier, M | 1 |
| Lebel, M | 1 |
| Larbrisseau, A | 1 |
| Curran, MA | 1 |
| Winter, RM | 1 |
| Tucker, SM | 1 |
| Ardinger, HH | 1 |
| Atkin, JF | 1 |
| Blackston, RD | 1 |
| Elsas, LJ | 1 |
| Clarren, SK | 1 |
| Livingstone, S | 1 |
| Flannery, DB | 1 |
| Pellock, JM | 1 |
| Harrod, MJ | 1 |
| Tsuru, N | 1 |
| Maeda, T | 1 |
| Tsuruoka, M | 1 |
| Wladimiroff, JW | 1 |
| Stewart, PA | 1 |
| Reuss, A | 1 |
| van Swaay, E | 1 |
| Sachs, ES | 1 |
| Chitayat, D | 1 |
| Farrell, K | 1 |
| Anderson, L | 1 |
| Hall, JG | 1 |
| Wellesley, D | 1 |
| Binkerd, P | 1 |
| Rowland, JM | 1 |
| Rowland, JR | 1 |
| Cukierski, MJ | 1 |
| Jallon, P | 1 |
| Goujard, J | 1 |
| Farmer, PB | 1 |
| Coakley, M | 1 |
| Pillans, PI | 1 |
| Kola, I | 1 |
| Segni, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PSG in Valproate-induced Nocturnal Enuresis in Children[NCT04191863] | 260 participants (Actual) | Observational | 2018-09-01 | Completed | |||
| Lamotrigine Pregnancy Registry (LAM05)[NCT01064297] | 3,416 participants (Actual) | Observational | 2001-11-30 | Completed | |||
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| Neurodevelopmental Effects of Antiepileptic Drugs II: the NEAD Study[NCT00021866] | 331 participants (Actual) | Observational | 2000-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of infants with major congenital malformations were counted and are presented by earliest trimester of exposure to lamotrigine polytherapy with valproate. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) |
|---|---|
| First Exposure During First Trimester | 14 |
| First Exposure During Second Trimester | 1 |
| First Exposure During Third Trimester | 0 |
| Unspecified Trimester of Exposure | 0 |
| All Trimesters | 1 |
The number of infants with major congenital malformations were counted and are presented by earliest trimester of exposure to lamotrigine polytherapy without valproate. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) |
|---|---|
| First Exposure During First Trimester | 12 |
| First Exposure During Second Trimester | 0 |
| First Exposure During Third Trimester | 1 |
| All Trimesters | 13 |
Among lamotrigine monotherapy exposures: live births, fetal deaths, induced abortions with birth defects, and live births without defects. Due to the likelihood of inconsistent identification of birth defects among spontaneous losses, fetal deaths, and induced abortions without reported birth defects, these offspring were not included in analyses. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) |
|---|---|
| First Exposure During First Trimester | 35 |
| First Exposure During Second Trimester | 4 |
| First Exposure During Third Trimester | 1 |
| Unspecified Trimester of Exposure | 0 |
| All Trimesters | 40 |
The number of live births, fetal deaths, induced abortions, and spontaneous pregnancy losses were recorded according to the time at which women were first exposed to lamotrigine monotherapy. Due to inconsistent identification of major congenital malformations (MCMs) among spontaneous losses, no comment is made concerning the presence or absence of MCMs. (NCT01064297)
Timeframe: Although reports and diagnoses of major congenital malformations are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Live Birth (Birth Defects Reported) | Fetal Death (Birth Defects Reported) | Induced Abortion (Birth Defects Reported) | Live Birth (No Birth Defects Reported) | Fetal Death (No Birth Defects Reported) | Induced Abortion (No Birth Defects Reported) | Spontaneous Pregnancy Loss | |
| First Exposure During First Trimester | 31 | 1 | 3 | 1523 | 10 | 33 | 98 |
| First Exposure During Second Trimester | 4 | 0 | 0 | 91 | 0 | 0 | 0 |
| First Exposure During Third Trimester | 1 | 0 | 0 | 17 | 0 | 0 | 0 |
| Unspecified Trimester of Exposure | 0 | 0 | 0 | 5 | 0 | 0 | 0 |
The number of live births, fetal deaths, induced abortions, and spontaneous pregnancy losses were recorded according to the time at which women were first exposed to lamotrigine polytherapy with valproate. Due to inconsistent identification of major congenital malformations (MCMs) among spontaneous losses, no comment is made concerning the presence or absence of MCMs. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Live Birth (Birth Defects Reported) | Fetal Death (Birth Defects Reported) | Induced Abortion (Birth Defects Reported) | Live Birth (No Birth Defects Reported) | Fetal Death (No Birth Defects Reported) | Induced Abortion (No Birth Defects Reported) | Spontaneous Pregnancy Loss | |
| First Exposure During First Trimester | 14 | 0 | 2 | 134 | 1 | 4 | 6 |
| First Exposure During Second Trimester | 1 | 0 | 0 | 6 | 1 | 0 | 0 |
| First Exposure During Third Trimester | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Unspecified Trimester of Exposure | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
The number of live births, fetal deaths with pregnancy loss occurring >=20 weeks gestation, induced abortions, and spontaneous pregnancy losses were recorded according to the time at which women were first exposed to lamotrigine polytherapy without valproate. Due to inconsistent identification of major congenital malformations (MCMs) among spontaneous losses, no comment is made concerning the presence or absence of MCMs. Although birth defects may not have been reported, they cannot be ruled out. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Live Birth (Birth Defects Reported) | Fetal Death (Birth Defects Reported) | Induced Abortion (Birth Defects Reported) | Live Birth (No Birth Defects Reported) | Fetal Death (No Birth Defects Reported) | Induced Abortion (No Birth Defects Reported) | Spontaneous Pregnancy Loss | |
| First Exposure During First Trimester | 11 | 0 | 1 | 418 | 3 | 19 | 22 |
| First Exposure During Second Trimester | 0 | 0 | 0 | 25 | 0 | 0 | 0 |
| First Exposure During Third Trimester | 1 | 0 | 0 | 2 | 0 | 0 | 0 |
The number of infants with the reported MCM following first trimester exposure to lamotrigine polytherapy with valproate were counted. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hydrocephalus/spina bifida | Meningomyelocele | Microcephaly | Orofacial clefts | Cardiac septal defects | Transposition of great vessels | Ventricular hypoplasia | Pulmonary stenosis | Pyloric stenosis | Gastroschisis | Club foot | Polydactyly | |
| Doses Lower Than Prescribed | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| Prescribed Doses | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The number of infants with the reported MCM following first trimester exposure to lamotrigine polytherapy without valproate were counted. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Neural tube defect | Cardiac septal defect/murmur | Coarctation of aorta | Tetralogy of Fallot | Esophageal defects | Hypospadias | Hydroencephalopathy | Omphalocele | Extra digit | Skin tags on ear | |
| Doses Higher Than Prescribed | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 |
| Doses Lower Than Prescribed | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Prescribed Doses | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
The number of infants with the reported MCM following first trimester lamotrigine monotherapy exposure were counted. Registry personnel contacted the enrolling physician to obtain information on the pregnancy outcome, lamotrigine dosing and duration of exposure, and use of concomitant antiepileptic drugs during pregnancy. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anencephaly | Orofacial clefts | Hypoplastic left heart/left ventricle hypoplasia | Transposition of great vessels | Ventricular septal defects | Minor heart defect, unspecified | Pulmonary stenosis | Hydronephrosis | Renal defect (absent, polysystic, fluid on kidney) | Cortical dysplasis | Hypospadias | Pyloric stenosis | Diaphragmatic hernia | Congenital atresia of anus | Hip dislocation | Club feet | Polydactyly | Epidermolysis bullosa | Light spot across entire abdomen | |
| Dose Higher Than Prescribed | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Doses Lower Than Prescribed | 2 | 2 | 1 | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 |
| Prescribed Doses | 0 | 0 | 0 | 0 | 3 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 |
| Unknown Maximal Dose in Exposed Trimester | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
52 reviews available for valproic acid and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Epilepsy in Pregnancy-Management Principles and Focus on Valproate.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Autism | 2022 |
Genetic/idiopathic generalized epilepsies: Not so good as that!
Topics: Abnormalities, Drug-Induced; Adult; Comorbidity; Contraindications, Drug; Death, Sudden; Epilepsy, G | 2020 |
Teratology of valproic acid: an updated review of the possible mediating mechanisms.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Antineoplastic Agents; Female; Humans; Neopla | 2018 |
Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Infant, Newbo | 2017 |
Valproic Acid in Women and Girls of Childbearing Age.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Antimanic Agents; Europe; Female; H | 2017 |
Sodium valproate in pregnancy: what are the risks and should we use a shared decision-making approach?
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Decision Making; E | 2018 |
Is post exposure prevention of teratogenic damage possible: Studies on diabetes, valproic acid, alcohol and anti folates in pregnancy: Animal studies with reflection to human.
Topics: Abnormalities, Drug-Induced; Animals; Antioxidants; Diabetes, Gestational; Ethanol; Ethyl Ethers; Fe | 2018 |
'Conceivably Neglected' - Are prescribers sufficiently aware of the risks of prescribing sodium valproate to women with mental illness?
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Epilepsy; Female; | 2019 |
Arrhenius thermodynamics and birth defects: chemical teratogen synergy. Untested, testable, and projected relevance.
Topics: Abnormalities, Drug-Induced; Animals; Congenital Abnormalities; Drug Synergism; Female; Fever; Human | 2013 |
Prediction of the hazard of foetal malformation in pregnant women with epilepsy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Australia; Epilepsy; Female; Humans; Pregnancy; | 2014 |
Risks of congenital malformations in offspring exposed to valproic acid in utero: A systematic review and cumulative meta-analysis.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Female; Humans; Maternal Exposure; Odds Ratio; Pregnan | 2015 |
Is carbamazepine a human teratogen?
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Australia; Carbamazepine; Epilepsy; Female; Fet | 2016 |
Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Humans; Pregnancy; Prenatal Exposure | 2016 |
Guideline adherence for mentally ill reproductive-aged women on treatment with valproic acid: a retrospective chart review.
Topics: Abnormalities, Drug-Induced; Contraception Behavior; Female; Folic Acid; Guideline Adherence; Humans | 2016 |
Teratogenicity of antiepileptic medications.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Drug Interactions; Drug Therapy, Combination; Epilepsy | 2008 |
Epileptic disorders in pregnancy: an overview.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Epilepsy; Female; Folic Acid; Hemorrhag | 2008 |
Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Birth Weight; Cognition Disorders; Contraindications; | 2009 |
Valproic acid in pregnancy: how much are we endangering the embryo and fetus?
Topics: Abnormalities, Drug-Induced; Adolescent; Animals; Anticonvulsants; Autistic Disorder; Child; Child D | 2009 |
Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurolo
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Birth Weight; Cognition Disorders; Contraindications; | 2009 |
The teratogenic risk of antiepileptic drug polytherapy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Drug Therapy, Combination; Female; Fetal Di | 2010 |
Valproic acid monotherapy in pregnancy and major congenital malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Case-Control Studies; Cohort Studies; Female; Humans; | 2010 |
Potency ranking of valproic acid analogues as to inhibition of cardiac differentiation of embryonic stem cells in comparison to their in vivo embryotoxicity.
Topics: Abnormalities, Drug-Induced; Animal Testing Alternatives; Animals; Cell Differentiation; Cell Line; | 2011 |
[Effect of anti-epileptic drugs on human placenta and the fetus].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Embryonic and Fetal Development; Epilepsy; Female; Fet | 2004 |
[Therapy of epilepsy: current strategy and tactics].
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Age Factors; Anticonvulsants; Carbamazepine; Child; | 2004 |
Teratogenicity of sodium valproate.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Animals; Autistic Disorder; Cleft Lip; | 2005 |
Valproic acid in epilepsy : pregnancy-related issues.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Autistic Disorder; Epilepsy; Female; Humans; Infant, N | 2006 |
Major malformations with valproic acid.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Antimanic Agents; Developmental Disabilities; Dose-Res | 2006 |
Antiepileptic drugs as human teratogens.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Phenobarbital | 2008 |
Drug exposure during pregnancy: some epidemiologic considerations.
Topics: Abnormalities, Drug-Induced; Benzodiazepines; Caffeine; Dicyclomine; Doxylamine; Drug Combinations; | 1983 |
The epileptic mother and her child.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Breast Feeding; Carbamazepine; Epilepsy; Female; Fetal | 1982 |
Pregnancy, teratogenesis, and epilepsy.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Epilepsy; Female; Fetus; Humans; Infant, Newb | 1994 |
The teratogenic effects of valproic acid in human chondrogenesis in vitro.
Topics: Abnormalities, Drug-Induced; Animals; Cartilage; Cell Aggregation; Cell Differentiation; Cells, Cult | 1994 |
The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity.
Topics: Abnormalities, Drug-Induced; Acetaminophen; Chemical and Drug Induced Liver Injury; Cytochrome P-450 | 1995 |
Special considerations: use of lithium in children, adolescents, and elderly populations.
Topics: Abnormalities, Drug-Induced; Acetates; Adolescent; Adult; Age Factors; Aged; Amines; Anticonvulsants | 1998 |
[Fetal valproate syndrome].
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Anticonvulsants; Diagnosis, Differential; Fema | 2000 |
Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Anticonvulsants; Epilepsy; Face; Female | 2001 |
Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants.
Topics: Abnormalities, Drug-Induced; Acetates; Adult; Amines; Antimanic Agents; Benzodiazepines; Breast Feed | 2001 |
[Fetal valproate syndrome].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Female; Fetal Diseases; Humans; Infant, Newborn; Pregn | 2001 |
Molecular basis of environmentally induced birth defects.
Topics: Abnormalities, Drug-Induced; Animals; Embryonic and Fetal Development; Female; Gene Expression Regul | 2002 |
[Valproic acid and pregnancy: an unresolved problem. A clinical case].
Topics: Abnormalities, Drug-Induced; Adolescent; Cesarean Section; Epilepsy; Female; Humans; Infant, Newborn | 1992 |
Differentiation between valproate-induced anticonvulsant effect, teratogenicity and hepatotoxicity. Aspects of species variation, pharmacokinetics, metabolism and implications of structural specificity for the development of alternative antiepileptic agen
Topics: Abnormalities, Drug-Induced; Aging; Animals; Anticonvulsants; Humans; Liver; Structure-Activity Rela | 1992 |
Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms.
Topics: Abnormalities, Drug-Induced; Animals; Disease Models, Animal; Female; Humans; Maternal-Fetal Exchang | 1991 |
Valproic acid prenatal exposure. Association with lipomyelomeningocele.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Anticonvulsants; Cleft Palate; Female; | 1989 |
[Fetal disease caused by sodium valproate. Apropos of a case].
Topics: Abnormalities, Drug-Induced; Epilepsy; Female; Humans; Infant, Newborn; Pregnancy; Pregnancy Complic | 1989 |
[Problems of neurological drug therapy in pregnancy].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Antiparkinson Agents; Carbamazepine; Chelating Agents; | 1989 |
Valproate: an updated review.
Topics: Abnormalities, Drug-Induced; Brain Diseases; Chemical and Drug Induced Liver Injury; Coma; Dyskinesi | 1985 |
Use of ethosuximide and valproate in the treatment of epilepsy.
Topics: Abnormalities, Drug-Induced; Brain Diseases; Drug Interactions; Epilepsies, Myoclonic; Epilepsies, P | 1986 |
Teratogen update: valproic acid.
Topics: Abnormalities, Drug-Induced; Animals; Epidemiologic Methods; Epilepsy; Female; Humans; Infant, Newbo | 1987 |
Congenital malformations associated with maternal use of valproic acid.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Bone and Bones; Epilepsy; Facial Bones; Female | 1987 |
Verification of the fetal valproate syndrome phenotype.
Topics: Abnormalities, Drug-Induced; Facial Bones; Female; Growth Disorders; Humans; Infant; Infant, Newborn | 1988 |
[Pharmacokinetic principles of the teratogenicity of drugs].
Topics: Abnormalities, Drug-Induced; Animals; Female; Humans; Maternal-Fetal Exchange; Pregnancy; Species Sp | 1988 |
Three cases of delivery under sodium valproate--placental transfer, milk transfer and probable teratogenicity of sodium valproate.
Topics: Abnormalities, Drug-Induced; Adult; Epilepsy; Female; Fingers; Humans; Infant, Newborn; Male; Matern | 1988 |
2 trials available for valproic acid and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
In utero antiepileptic drug exposure: fetal death and malformations.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Carbamazepine; Cognition; Female; Fetal Death; | 2006 |
[Anti-epileptic agents during pregnancy. A prospective study on the course of pregnancy, malformations and child development].
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Akathisia, Drug-Induced; Anencephaly; Ant | 1983 |
314 other studies available for valproic acid and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Epilepsy, Complex Partial; Mice; Rats; Stereo | 2007 |
Alpha-fluoro-2,2,3,3-tetramethylcyclopropanecarboxamide, a novel potent anticonvulsant derivative of a cyclic analogue of valproic acid.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Cyclopropanes; Epilepsy; Male; Mice; Rats; Ra | 2009 |
Transgenerational adverse effects of valproate? A patient report from 90 affected families.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Cleft Lip; Cleft Palate; Drug-Related Side Ef | 2022 |
Modified Xenopus laevis approach (R-FETAX) as an alternative test for the evaluation of foetal valproate spectrum disorder.
Topics: Abnormalities, Drug-Induced; Animals; Behavior, Animal; Disease Models, Animal; Embryo, Nonmammalian | 2022 |
Establishing or Excluding a Diagnosis of Fetal Valproate Spectrum Disorder is a Multi-layered Process.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Female; Humans; Pregnancy; Valproic Acid | 2021 |
Valproate Teratogenicity: A Moving Target.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Humans; Pregnancy; Pregnancy Complic | 2022 |
Spontaneous Partial Regression of Bilateral Grade III Corneal Dermoids Associated With Fetal Valproate Spectrum Disorder.
Topics: Abnormalities, Drug-Induced; Child; Choristoma; Corneal Diseases; Dermoid Cyst; Female; Growth Disor | 2022 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Proposal for reference values for the developmental effects of valproate based on human data using a benchmark dose approach.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benchmarking; Female; Humans; Pregnancy; Pregnancy Com | 2023 |
Specific fetal malformations following intrauterine exposure to antiseizure medication.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Carbamazepine; Female; Humans; Male; Pregna | 2023 |
Exome sequencing in patients with antiepileptic drug exposure and complex phenotypes.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Child; Child, Preschool; Developmental Disabilities; E | 2020 |
Radial Ray Malformation.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Amniocentesis; Amniotic Band Syndrome; Anal Ca | 2019 |
Standard of Care: Reasonable But Not Perfect.
Topics: Abnormalities, Drug-Induced; Adult; Arnold-Chiari Malformation; Female; Humans; Hydrocephalus; Infan | 2020 |
Pregnancy after valproate withdrawal-Fetal malformations and seizure control.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Australia; Epilepsy; Female; Humans; Pregnancy; | 2020 |
A rat model of valproate teratogenicity from chronic oral treatment during pregnancy.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Anticonvulsants; Disease Models, Animal; | 2020 |
Role of Cbp, p300 and Akt in valproic acid induced neural tube defects in CD-1 mouse embryos.
Topics: Abnormalities, Drug-Induced; Animals; CREB-Binding Protein; Down-Regulation; E1A-Associated p300 Pro | 2020 |
Sodium valproate prescription to women of childbearing age in a New Zealand inpatient psychiatric unit.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Clinical Audit; | 2020 |
Cumberlege review exposes stubborn and dangerous flaws in healthcare.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Delivery of Health Care; England; Humans; Legislation, | 2020 |
Folic acid dose, valproate, and fetal malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Female; Folic Acid; Humans; Pregnancy; Preg | 2021 |
Active Surveillance of the Safety of Medications Used During Pregnancy.
Topics: Abnormalities, Drug-Induced; Analgesics, Opioid; Cohort Studies; Data Mining; Databases, Factual; Fe | 2021 |
Fetal valproate syndrome with coronary arteriovenous fistula: a case report.
Topics: Abnormalities, Drug-Induced; Arteriovenous Fistula; Female; Humans; Pregnancy; Pregnancy Trimester, | 2021 |
Multistate models of developmental toxicity: Application to valproic acid-induced malformations in the zebrafish embryo.
Topics: Abnormalities, Drug-Induced; Animals; Bayes Theorem; Computer Simulation; Dose-Response Relationship | 2021 |
Valproate usage in pregnancy: An audit from the Kerala Registry of Epilepsy and Pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Epilepsy; Female; Humans; India; Pregnancy; Pre | 2021 |
The contribution of non-drug factors to fetal malformation in anti-seizure-medication-treated pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Australia; Epilepsy; Female; Humans; Pregnancy; | 2021 |
Awareness, knowledge and practice of healthcare professionals following implementation of a Pregnancy Prevention Program for sodium valproate in Ireland: a multi-stakeholder cross-sectional study.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Cross-Sectional Studies; Female; General Practitioners | 2021 |
Contemporary trends in antiepileptic drug treatment among women of childbearing age with epilepsy in the United States: 2004-2015.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Epilepsy; Female; Humans; Pregnancy; Pregnancy | 2021 |
Characterizing the effects of in utero valproic acid exposure on murine fetoplacental development.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Female; Fetal Development; Fetus; Male; Mater | 2021 |
Exposure to Sodium Valproate during Pregnancy: Facial Features and Signs of Autism.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Autism Spectrum Disorder; Autistic | 2017 |
France bans sodium valproate use in case of pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Bipolar Disorder; Female; France; Humans; Pregnancy; P | 2017 |
Women still not being told about pregnancy risks of valproate.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Developmental Disabilities; Epilepsy; Female; Humans; | 2017 |
Activities of Proline-Specific Proteinases in the Serum and Cerebrospinal Fluid of Rats with the Fetal Valproate Syndrome.
Topics: Abnormalities, Drug-Induced; Animals; Dipeptidyl Peptidase 4; Male; Prolyl Oligopeptidases; Rats; Ra | 2017 |
Fetal Valproate Syndrome - Still a Problem Today!
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Cesarean Section; Drug Therapy, Combination; Ep | 2017 |
Repairability of skeletal alterations induced by sodium valproate in rats.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Alcian Blue; Animals; Animals, Newborn; Anthraqui | 2018 |
Fetal valproate syndrome: the Irish experience.
Topics: Abnormalities, Drug-Induced; Female; Humans; Ireland; Male; Pregnancy; Retrospective Studies; Syndro | 2018 |
Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications.
Topics: Abnormalities, Drug-Induced; Dose-Response Relationship, Drug; Epilepsy; Female; Humans; Outcome Ass | 2018 |
A UK clinical audit addressing the quality of prescribing of sodium valproate for bipolar disorder in women of childbearing age.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Age Factors; Antimanic Agents; Bipolar Disorder; Cli | 2018 |
Weighing the risks of valproate in women who could become pregnant.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Contraindications, Drug; Developmental Disabilities; E | 2018 |
Dangers of valproate in pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Humans; Pregnancy; Pregnancy Complic | 2018 |
Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug | 2018 |
Reducing valproate use in women with epilepsy.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Drug Utilization; Epilepsy; Female; | 2018 |
Valproate-associated foetal malformations-Rates of occurrence, risks in attempted avoidance.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Australia; Epilepsy; Female; Humans; Pregnancy; | 2019 |
Fetal valproate syndrome as a phenocopy of Kleefstra syndrome.
Topics: Abnormalities, Drug-Induced; Adult; Child, Preschool; Chromosome Deletion; Chromosomes, Human, Pair | 2018 |
Teratogenicity of valproic acid and its constitutional isomer, amide derivative valnoctamide in mice.
Topics: Abnormalities, Drug-Induced; Amides; Animals; Anticonvulsants; Female; Fetal Death; Fetus; Mice; Neu | 2019 |
Sodium valproate: who knew what and when? Cumulative meta-analysis gives extra insights.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Humans; Meta-Analysis as Topic; Preg | 2019 |
Valproate and the Pregnancy Prevention Programme: exceptional circumstances.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Drug and Narcotic Control; Europe; Female; Humans; Pre | 2019 |
Why do some women with epilepsy use valproic acid despite current guidelines? A single-center cohort study.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Cohort Studies; Epilepsy; Female; H | 2019 |
Associations between particular types of fetal malformation and antiepileptic drug exposure in utero.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Epilepsy; Female; Fetal Diseases; Fructose; | 2013 |
Dose dependence of fetal malformations associated with valproate.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Austria; Dose-Response Relationship, Drug; Epilepsy; F | 2013 |
Valproic acid silencing of ascl1b/Ascl1 results in the failure of serotonergic differentiation in a zebrafish model of fetal valproate syndrome.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Basic Helix-Loop-Helix Transcription Factors; | 2014 |
Malformation in index pregnancy in women with epilepsy is not followed by recurrence in subsequent pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; India; Pregna | 2013 |
Impact of planning of pregnancy in women with epilepsy on seizure control during pregnancy and on maternal and neonatal outcomes.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Humans; Pregnancy | 2014 |
Is coloboma a feature of fetal valproate syndrome?
Topics: Abnormalities, Drug-Induced; Child, Preschool; Coloboma; Humans; Male; Seizures; Valproic Acid | 2014 |
Difficult airway in an infant with fetal valproate syndrome.
Topics: Abnormalities, Drug-Induced; Airway Management; Anticonvulsants; Hernia, Inguinal; Humans; Infant; M | 2014 |
Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug | 2014 |
Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Birth Weight; Cohort Studies; Epilepsy; Female; | 2014 |
Resveratrol and vitamin E rescue valproic acid-induced teratogenicity: the mechanism of action.
Topics: Abnormalities, Drug-Induced; Animals; Antioxidants; Chick Embryo; Glutathione; Reactive Oxygen Speci | 2014 |
[Valproate should be avoided in pregnancy].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Humans; Pregnancy; Prenatal Exposure | 2014 |
Ocular coloboma and foetal valproate syndrome: four further cases and a hypothesis for aetiology.
Topics: Abnormalities, Drug-Induced; Coloboma; Humans; Male; Valproic Acid | 2014 |
The teratogenicity of the newer antiepileptic drugs - an update.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Epilepsy; Female; Fetus; Fructose; Humans; Lamo | 2014 |
Brief report novel mechanism for valproate-induced teratogenicity.
Topics: Abnormalities, Drug-Induced; Biological Availability; Cell Line; Embryonic Development; Female; Fola | 2014 |
Middle and inner ear malformations in two siblings exposed to valproic acid during pregnancy: a case report.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Child; Child, Preschool; Developmental Disabil | 2014 |
Valproate fetopathy.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Diagnostic Imaging; Epilepsy; Female; Fetal Di | 2015 |
Prevention of valproic acid-induced neural tube defects by sildenafil citrate.
Topics: Abnormalities, Drug-Induced; Animals; Bone and Bones; Disease Models, Animal; Dose-Response Relation | 2015 |
Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Dose-Response Relationship, Drug; D | 2015 |
New findings in fetal valproate syndrome: hiatal hernia, gastric volvulus and ectopic kidney.
Topics: Abnormalities, Drug-Induced; Adult; Female; Hernia, Hiatal; Humans; Infant, Newborn; Kidney; Male; P | 2016 |
France steps up warning measures for valproate drugs.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Drug and Narcotic Control; Drug Information Services; | 2016 |
Should women of childbearing potential be prescribed valproate? a call to action.
Topics: Abnormalities, Drug-Induced; Bipolar Disorder; Contraception Behavior; Epilepsy; Female; Humans; Inf | 2016 |
Effects of developmental alcohol and valproic acid exposure on play behavior of ferrets.
Topics: Abnormalities, Drug-Induced; Age Factors; Animals; Behavior, Animal; Disease Models, Animal; Ethanol | 2016 |
Antiepileptic drug combinations not involving valproate and the risk of fetal malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Cohort Studies; Dose-Response Relationship, Drug; Drug | 2016 |
Fetal Valproate Syndrome.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Child, Preschool; Craniofacial Abnormalities; Cryptorc | 2017 |
Prenatal sonographic diagnosis of fetal valproate syndrome: a case report.
Topics: Abnormalities, Drug-Induced; Adult; Female; Humans; Infant, Newborn; Japan; Pregnancy; Pregnancy Com | 2016 |
Combining adverse pregnancy and perinatal outcomes for women exposed to antiepileptic drugs during pregnancy, using a latent trait model.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Epilepsy; Female; Florida; Humans; Infant, Low | 2017 |
Intrauterine valproate exposure is associated with alterations in hippocampal cell numbers and folate metabolism in a rat model of valproate teratogenicity.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Astrocytes; Cell Count; Disease Models, Anima | 2017 |
Valproate teratogenicity and epilepsy syndrome.
Topics: Abnormalities, Drug-Induced; Age of Onset; Analysis of Variance; Anticonvulsants; Dose-Response Rela | 2008 |
Valproic acid increases expression of methylenetetrahydrofolate reductase (MTHFR) and induces lower teratogenicity in MTHFR deficiency.
Topics: Abnormalities, Drug-Induced; Animals; Brain; Cell Line, Tumor; Female; Folic Acid; Homocysteine; Hum | 2008 |
Tetramethylcyclopropyl analogue of the leading antiepileptic drug, valproic acid: evaluation of the teratogenic effects of its amide derivatives in NMRI mice.
Topics: Abnormalities, Drug-Induced; Amides; Animals; Anticonvulsants; Benzenesulfonamides; Cyclopropanes; D | 2008 |
Valproate and babies.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Bipolar Disorder; Cross-Sectional Studies; Dose-Respon | 2008 |
Fibular aplasia in a child exposed to sodium valproate in pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Female; Fibula; Humans; Infant; Maternal Exposu | 2009 |
[Valproate treatment during pregnancy: description of four cases with foetal valproate syndrome].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Child; Child, Preschool; Developmental Disabilities; E | 2009 |
Changing trends in antiepileptic drug prescribing in girls of child-bearing potential.
Topics: Abnormalities, Drug-Induced; Adolescent; Anticonvulsants; Carbamazepine; Child; Contraceptive Agents | 2009 |
Dose-dependent memory effects and cerebral volume changes after in utero exposure to valproate in the rat.
Topics: Abnormalities, Drug-Induced; Age Factors; Analysis of Variance; Animals; Animals, Newborn; Anticonvu | 2009 |
Pregnancy, delivery, and outcome for the child in maternal epilepsy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Apgar Score; Birth Weight; Congenital Abnormali | 2009 |
[Fetal malformations in women with epilepsy].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Bulgaria; Carbamazepine; Epilepsy; Female; Humans; Inf | 2009 |
Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; DNA Damage; Female; Fructose; Histone Deacetylase Inhi | 2009 |
Pregnancy treatment guidelines: throwing the baby out with the bath water.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Femal | 2009 |
Unilateral lung agenesis: coincidence or association with maternal valproate therapy?
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Humans; Infant, Newborn; Lung; Male; | 2009 |
Anticonvulsant profile and teratogenic evaluation of potent new analogues of a valproic acid urea derivative in NMRI mice.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Bone and Bones; Deep Sedation; Differential T | 2009 |
VPA-related axial skeletal defects and apoptosis: a proposed event cascade.
Topics: Abnormalities, Drug-Induced; Acetylation; Animals; Anticonvulsants; Apoptosis; Blotting, Western; Bo | 2010 |
Valproic acid: long-term effects on children exposed in utero.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Cohort Studies; Contraindications; Dose | 2009 |
Genetic and maternal effects on valproic acid teratogenesis in C57BL/6J and DBA/2J mice.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Blotting, Western; Dose-Response Relationship | 2010 |
[Valproate for treatment of women with epilepsy: recommendations of the German Society for Epileptology].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, Combin | 2010 |
Does folic acid use decrease the risk for spina bifida after in utero exposure to valproic acid?
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Case-Control Studies; Dietary Supplements; Female; Fol | 2010 |
Epigenetic modifications in valproic acid-induced teratogenesis.
Topics: Abnormalities, Drug-Induced; Acetylation; Animals; Epigenesis, Genetic; Female; Histones; Mice; Neur | 2010 |
Comparative pharmacodynamic and pharmacokinetic analysis of two anticonvulsant halo derivatives of 2,2,3,3-tetramethylcyclopropanecarboxamide, an amide of a cyclic analog of valproic acid.
Topics: Abnormalities, Drug-Induced; Amides; Analgesics; Animals; Anticonvulsants; Cyclopropanes; Disease Mo | 2010 |
Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Congenital Abnormalities; Dose-Response Rel | 2010 |
Valproic acid use in pregnancy and congenital malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Female; Humans; Infant, Newborn; Pregnancy; Pregnancy | 2010 |
Trial against epilepsy drug manufacturer collapses after legal aid is withdrawn.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Child; Compensation and Redress; Drug Industry; Humans | 2010 |
Severe fetal valproate syndrome: combination of complex cardiac defect, multicystic dysplastic kidney, and trigonocephaly.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Craniosynostoses; Fatal Outcome; Female; Heart | 2011 |
Short-time gene expression response to valproic acid and valproic acid analogs in mouse embryonic stem cells.
Topics: Abnormalities, Drug-Induced; Animals; Butyrates; Cell Line; Embryonic Development; Embryonic Stem Ce | 2011 |
Final results from 18 years of the International Lamotrigine Pregnancy Registry.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Female; Humans; Infant; Lamotrigine; Pregnanc | 2011 |
Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Epile | 2011 |
Antiepileptic drug use during pregnancy: perinatal outcomes.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Carbamazepine; Cohort Studies; Drug | 2011 |
The prescribing of antiepileptic drugs for pregnant Australian women.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Australia; Epilepsy; Female; Fetus; Humans; Log | 2012 |
Synaptic and intrinsic balancing during postnatal development in rat pups exposed to valproic acid in utero.
Topics: Abnormalities, Drug-Induced; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Fema | 2011 |
Use of antiepileptic medications in pregnancy in relation to risks of birth defects.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Hu | 2011 |
Rare but real--the effects of sodium valproate in pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Female; Humans; Maternal-Fetal Exchange; Pregnancy; Va | 2011 |
Developmental exposure to valproate and ethanol alters locomotor activity and retino-tectal projection area in zebrafish embryos.
Topics: Abnormalities, Drug-Induced; Animals; Embryo, Nonmammalian; Ethanol; Motor Activity; Retina; Superio | 2012 |
Valproate-induced teratogenesis in Japanese rice fish (Oryzias latipes) embryogenesis.
Topics: Abnormalities, Drug-Induced; Animals; Cardiovascular Abnormalities; Cell Cycle Proteins; Embryo, Non | 2012 |
Valproate and the risk for congenital malformations: Is formulation and dosage regime important?
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Humans; Pregnancy; Pregnancy Complic | 2012 |
Economic evaluation of anti-epileptic drug therapies with specific focus on teratogenic outcomes.
Topics: Abnormalities, Drug-Induced; Adolescent; Anticonvulsants; Carbamazepine; Cost-Benefit Analysis; Epil | 2012 |
An anomalous left superior venacava draining into left atrium in association with fetal valproate syndrome.
Topics: Abnormalities, Drug-Induced; Female; Heart Atria; Humans; Infant, Newborn; Pregnancy; Valproic Acid; | 2013 |
Epigenetic changes and disturbed neural development in a human embryonic stem cell-based model relating to the fetal valproate syndrome.
Topics: Abnormalities, Drug-Induced; Antigens, Differentiation; Basic Helix-Loop-Helix Transcription Factors | 2012 |
Teratogenesis in repeated pregnancies in antiepileptic drug-treated women.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Epilepsy; Female; Humans; Parity; Pregnancy | 2013 |
Valproic acid downregulates RBP4 and elicits hypervitaminosis A-teratogenesis--a kinetic analysis on retinol/retinoic acid homeostatic system.
Topics: Abnormalities, Drug-Induced; Animals; Chick Embryo; Embryonic Development; Histone Deacetylases; Hom | 2012 |
[Stigmata of dysembryogenesis and physical development in children born to mothers with epilepsy].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Child Development; Child, Preschool; Developmental Dis | 2011 |
Spirulina (arthrospira) protects against valproic acid-induced neural tube defects in mice.
Topics: Abnormalities, Drug-Induced; Animals; Antioxidants; Female; Fetus; Lipid Peroxidation; Mice; Mice, I | 2012 |
Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Drug Therapy, Combination; Epilepsy, Generalize | 2013 |
Antiepileptic drugs (AEDs) during pregnancy and risk of congenital jaw and oral malformation.
Topics: Abnormalities, Drug-Induced; Adverse Drug Reaction Reporting Systems; Amines; Anticonvulsants; Cyclo | 2013 |
Valproate embryopathy in three sets of siblings: further proof of hereditary susceptibility.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Child; Child, Preschool; Developmental Disabil | 2002 |
Nuchal edema as the first sign of fetal valproate syndrome.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Edema; Female; Gestational Age; Humans; Neck; P | 2002 |
Outcome of pregnancy in women attending an outpatient epilepsy clinic: adverse features associated with higher doses of sodium valproate.
Topics: Abnormalities, Drug-Induced; Adolescent; Anticonvulsants; Child; Child, Preschool; Dose-Response Rel | 2002 |
Valproic acid and lamotrigine treatment during pregnancy. The risk of chromosomal abnormality.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Anticonvulsants; Chromosome Aberrations | 2003 |
Major malformations in offspring of women with epilepsy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Carbamazepine; Comorbidity; Educational Status; | 2003 |
Amelioration of sodium valproate-induced neural tube defects in mouse fetuses by maternal folic acid supplementation during gestation.
Topics: Abnormalities, Drug-Induced; Animals; Brain; Dietary Supplements; Disease Models, Animal; Enzyme Inh | 2003 |
Congenital nasolacrimal duct obstruction requiring external dacryocystorhinostomies in a child with foetal valproate syndrome.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Dacryocystorhinostomy; Female; Humans; Infant; Lacrima | 2003 |
Postimplantation whole embryo culture assay for hamsters: an alternative to rat and mouse.
Topics: Abnormalities, Drug-Induced; Animals; Cadmium Chloride; Cricetinae; Culture Techniques; Diethylstilb | 2001 |
Patent ductus arteriosus in fetal valproate syndrome.
Topics: Abnormalities, Drug-Induced; Adult; Arm; Ductus Arteriosus, Patent; Female; Head; Humans; Infant, Ne | 2003 |
[Influence of valproic acid (depakine I.V.) on human placenta metabolism--experimental model].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Blood Glucose; Embryo, Mammalian; Embryonic and Fetal | 2003 |
[Fetal valproate syndrome].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Humans; Maternal-Fetal Exchange; Pre | 2003 |
Axial skeletal and Hox expression domain alterations induced by retinoic acid, valproic acid, and bromoxynil during murine development.
Topics: Abnormalities, Drug-Induced; Animals; Dose-Response Relationship, Drug; Female; Gene Expression Regu | 2003 |
Neurobehavioral teratogenicity in antiepileptic drugs: the new Pandora's box.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Child; Developmental Disabilities; Dose-Respons | 2004 |
Valproate-induced neural tube defects in folate-binding protein-2 (Folbp2) knockout mice.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Carrier Proteins; Diet; Disease Models, Anima | 2003 |
Chemically induced supernumerary lumbar ribs in CD-1 mice: size distribution and dose response.
Topics: 2,4-Dinitrophenol; Abnormalities, Drug-Induced; Animals; Benomyl; Dose-Response Relationship, Drug; | 2004 |
Amidic modification of valproic acid reduces skeletal teratogenicity in mice.
Topics: Abnormalities, Drug-Induced; Amides; Animals; Anticonvulsants; Bone and Bones; Cartilage; Cesarean S | 2004 |
Teratogenicity of valproate conjugates with anticonvulsant activity in mice.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Female; Lethal Dose 50; Male; Mice; Pregnancy | 2003 |
Effect of valproic acid on fetal and maternal organs in the mouse: a morphological study.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Animals; Female; Fetus; Gestational Age; Growt | 2004 |
Experimental studies on cervical and lumbar ribs in mouse embryos.
Topics: Abnormalities, Drug-Induced; Animals; Embryo, Mammalian; Fetus; Mice; Radiography; Ribs; Teratogens; | 2004 |
Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Carbamazepine; Child; Cohort Studies; Confoundi | 2004 |
Longer term outcome of children born to mothers with epilepsy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Epilepsy; Fema | 2004 |
The longer term outcome of children born to mothers with epilepsy.
Topics: Abnormalities, Drug-Induced; Adolescent; Anticonvulsants; Child; Child, Preschool; Cognition Disorde | 2004 |
Australian pregnancy registry of women taking antiepileptic drugs.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Drug Therapy, Combination; Epilepsy; Female | 2004 |
Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Dose-Response Relationship, Drug; Epilepsy; | 2004 |
Polycomb homologs are involved in teratogenicity of valproic acid in mice.
Topics: Abnormalities, Drug-Induced; Amides; Animals; Anticonvulsants; Bone and Bones; DNA-Binding Proteins; | 2004 |
Valproate embryopathy: clinical and cognitive profile in 5 siblings.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Anticonvulsants; Child; Child Behavior; Child, | 2005 |
Baller-Gerold syndrome after fetal exposure to sodium valproate.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Anticonvulsants; Craniosynostoses; Female; Hum | 2005 |
What can we say to women of reproductive age with epilepsy?
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Dose-Response Relationship, Drug; E | 2005 |
Increased rate of major malformations in offspring exposed to valproate during pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Epilepsy; Female; Humans; Infant, Newborn; Inte | 2005 |
Identification of early-responsive genes correlated to valproic acid-induced neural tube defects in mice.
Topics: Abnormalities, Drug-Induced; Amides; Animals; Embryo, Mammalian; Female; Gene Expression; Gene Expre | 2005 |
Association of valproate-induced teratogenesis with histone deacetylase inhibition in vivo.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Enzyme Inhibitors; Female; Gene Expression Pr | 2005 |
Antiepileptic drug use of women with epilepsy and congenital malformations in offspring.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Cardiovascular Abnormalities; Cleft Palate; Coh | 2005 |
Maternal valproate dosage and foetal malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Humans; Logistic Models; Pregnancy; | 2005 |
Preclinical profiling and safety studies of ABT-769: a compound with potential for broad-spectrum antiepileptic activity.
Topics: Abnormalities, Drug-Induced; Amygdala; Animals; Anticonvulsants; Behavior, Animal; Disease Models, A | 2005 |
Inhibition of histone deacetylase activity on specific embryonic tissues as a new mechanism for teratogenicity.
Topics: Abnormalities, Drug-Induced; Acetylation; Animals; Bone and Bones; Cartilage; Enzyme Inhibitors; Fem | 2005 |
Valproic acid-induced skeletal malformations: associated gene expression cascades.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Bone and Bones; Dose-Response Relationship, D | 2005 |
Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsant syndromes.
Topics: Abnormalities, Drug-Induced; Adolescent; Anthropometry; Anticonvulsants; Carbamazepine; Child; Child | 2006 |
S-2-pentyl-4-pentynoic hydroxamic acid and its metabolite s-2-pentyl-4-pentynoic acid in the NMRI-exencephaly-mouse model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further valproic acid hydroxamates an
Topics: Abnormalities, Drug-Induced; Animals; Blood-Brain Barrier; Disease Models, Animal; Dose-Response Rel | 2006 |
Myo-inositol enhances teratogenicity of valproic acid in the mouse.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Anticonvulsants; Drug Synergism; Embryo | 2006 |
A case of fetal anticonvulsant syndrome with severe bilateral upper limb defect.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Fetal Diseases | 2006 |
Prenatal exposure to antiepileptic drugs.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Cognition Disorders; Diethylcarbamazine; Face; Female; | 2006 |
Effect of maternal exposure to homocystine on sodium valproate-induced neural tube defects in the mouse embryos.
Topics: Abnormalities, Drug-Induced; Animals; Brain; Disease Models, Animal; Dose-Response Relationship, Dru | 2006 |
Teratology study of derivatives of tetramethylcyclopropyl amide analogues of valproic acid in mice.
Topics: Abnormalities, Drug-Induced; Amides; Animals; Body Weight; Cesarean Section; Cyclopropanes; Female; | 2006 |
Anticonvulsant activity, neural tube defect induction, mutagenicity and pharmacokinetics of a new potent antiepileptic drug, N-methoxy-2,2,3,3-tetramethylcyclopropane carboxamide.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Cyclopropanes; Female; Male; Mice; Mutagenesi | 2007 |
Valproic acid-induced fetal malformations are reduced by maternal immune stimulation with granulocyte-macrophage colony-stimulating factor or interferon-gamma.
Topics: Abnormalities, Drug-Induced; Adjuvants, Immunologic; Animals; Anticonvulsants; Dose-Response Relatio | 2006 |
Casting a broad network: fishing for mechanisms of retinoid teratogenicity.
Topics: Abnormalities, Drug-Induced; Animals; Diterpenes; Dose-Response Relationship, Drug; Gene Expression | 2006 |
Observations on juvenile myoclonic epilepsy amongst ethnic Bengalees in West Bengal--an Eastern Indian State.
Topics: Abnormalities, Drug-Induced; Age of Onset; Anticonvulsants; Benzodiazepines; Clobazam; Electroenceph | 2007 |
Boric acid inhibits embryonic histone deacetylases: a suggested mechanism to explain boric acid-related teratogenicity.
Topics: Abnormalities, Drug-Induced; Animals; Blotting, Western; Bone and Bones; Boric Acids; Cell Nucleus; | 2007 |
Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Carbamazepine; Cerebral Cortex; Female; Fetus | 2007 |
Early intervention for the ocular and neurodevelopmental sequelae of Fetal Valproate Syndrome.
Topics: Abnormalities, Drug-Induced; Amblyopia; Anticonvulsants; Autistic Disorder; Child, Preschool; Cranio | 2007 |
Informing patients of the teratogenic potential of mood stabilizing drugs: a case note review of the practice of psychiatrists.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Affect; Antimanic Agents; Carbamazepine; Counseling; | 2007 |
Pregnancy outcome after in utero exposure to valproate : evidence of dose relationship in teratogenic effect.
Topics: Abnormalities, Drug-Induced; Antimanic Agents; Dose-Response Relationship, Drug; Female; Humans; Pre | 2008 |
Teratogenic potential of valproic acid.
Topics: Abnormalities, Drug-Induced; Animals; Dose-Response Relationship, Drug; Female; Mice; Pregnancy; Val | 1980 |
Valproate and malformations.
Topics: Abnormalities, Drug-Induced; Epilepsy; Female; Humans; Infant, Newborn; Maternal-Fetal Exchange; Pre | 1982 |
Valproate, birth defects, and zinc.
Topics: Abnormalities, Drug-Induced; Female; Humans; Infant, Newborn; Maternal-Fetal Exchange; Pregnancy; Va | 1983 |
Valproate and birth defects.
Topics: Abnormalities, Drug-Induced; Female; Humans; Maternal-Fetal Exchange; Pregnancy; Valproic Acid | 1983 |
Spina bifida and in-utero exposure to valproate.
Topics: Abnormalities, Drug-Induced; Epilepsy; Female; Humans; Pregnancy; Pregnancy Complications; Spina Bif | 1984 |
Valproate and spina bifida.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Epilepsy; Female; Humans; Middle Aged; Pregnancy; Pr | 1984 |
Valproic acid and fetal abnormality.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Epilepsy; Female; Humans; Infant, Newbo | 1983 |
Valproic acid and metabolites: pharmacological and toxicological studies.
Topics: Abnormalities, Drug-Induced; Animals; Brain; Chemical and Drug Induced Liver Injury; Chemical Phenom | 1984 |
Valproate link to spina bifida.
Topics: Abnormalities, Drug-Induced; Female; Humans; Pregnancy; Risk; Spina Bifida Occulta; Valproic Acid | 1983 |
[Spina bifida caused by valproic acid?].
Topics: Abnormalities, Drug-Induced; Epilepsy; Female; Humans; Infant, Newborn; Pregnancy; Pregnancy Complic | 1983 |
Spina bifida and anencephaly: fewer patients, more problems.
Topics: Abnormalities, Drug-Induced; Anencephaly; Female; Humans; Infant, Newborn; Neural Tube Defects; Preg | 1983 |
Valproate: a new cause of birth defects--report from Italy and follow-up from France.
Topics: Abnormalities, Drug-Induced; Female; France; Humans; Infant, Newborn; Italy; Pregnancy; Spina Bifida | 1983 |
Antiepileptic drugs and teratogenesis. How should patients, doctors and health authorities be counselled?
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Infant, Newbo | 1983 |
[Case of congenital anomalies born to an epileptic woman treated with valproic acid and phenobarbital].
Topics: Abnormalities, Drug-Induced; Ear, External; Epilepsy; Esotropia; Female; Humans; Infant; Phenobarbit | 1983 |
[Is valproic acid teratogenic?].
Topics: Abnormalities, Drug-Induced; Adult; Dose-Response Relationship, Drug; Epilepsy; Female; Humans; Infa | 1983 |
Possible teratogenic effect of valproate during pregnancy.
Topics: Abnormalities, Drug-Induced; Epilepsy; Female; Humans; Infant, Newborn; Maternal-Fetal Exchange; Pre | 1983 |
Side effects of carbamazepine, valproate and clonazepam during long-term treatment of epilepsy.
Topics: Abnormalities, Drug-Induced; Arousal; Benzodiazepinones; Carbamazepine; Chemical and Drug Induced Li | 1983 |
Non-dose-related side effects of valproate.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Aged; Child; Child, Preschool; Epilepsy; Fat Necrosi | 1984 |
Rational use of valproate: indications and drug regimen in epilepsy.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Child; Child, | 1984 |
Valproic acid and congenital malformations. A case report.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Epilepsy; Female; Humans; Infant, Newbo | 1984 |
Teratogenic effects of dosage levels and time of administration of carbamazepine, sodium valproate, and diphenylhydantoin on craniofacial development in the CD-1 mouse fetus.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Dr | 1984 |
[Fertile women and valproate. Reactions to information about the possible teratogenic effect].
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Female; Humans; Neural Tube Defects; Pregnancy; Risk | 1984 |
[Use of valproic acid in pregnancy: an indication for prenatal diagnosis of spina bifida].
Topics: Abnormalities, Drug-Induced; Epilepsy; Female; Humans; Infant, Newborn; Pregnancy; Pregnancy Complic | 1984 |
[Use of valproic acid by pregnant women with epilepsy and the risk of congenital abnormalities in the child].
Topics: Abnormalities, Drug-Induced; Epilepsy; Female; Humans; Infant, Newborn; Pregnancy; Pregnancy Complic | 1984 |
Teratogenicity of valproic acid.
Topics: Abnormalities, Drug-Induced; Female; Humans; Infant, Newborn; Pregnancy; Pregnancy Complications; Se | 1980 |
Teratogenic effects of anticonvulsants.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Carbamazepine; Cleft Palate; Eyelid Diseases; | 1981 |
Possible teratogenicity of valproic acid.
Topics: Abnormalities, Drug-Induced; Adolescent; Female; Humans; Infant, Newborn; Male; Meningocele; Pregnan | 1981 |
Possible teratogenic effect of valproic acid.
Topics: Abnormalities, Drug-Induced; Adult; Female; Humans; Maternal-Fetal Exchange; Pregnancy; Valproic Aci | 1981 |
Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother's milk and clinical status in neonates of epileptic mothers.
Topics: Abnormalities, Drug-Induced; Aminopyrine; Breath Tests; Epilepsy; Female; Fetal Blood; Half-Life; Hu | 1981 |
American Academy of Pediatrics Committee on Drugs: Valproic acid: benefits and risks.
Topics: Abnormalities, Drug-Induced; Animals; Drug Interactions; Epilepsy; Humans; Valproic Acid | 1982 |
[Human teratogenicity of valproic acid containing antiepileptic drugs].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Humans; Pregnancy; Pregnancy Complic | 1982 |
[Valproate and congenital abnormalities].
Topics: Abnormalities, Drug-Induced; Carbamazepine; Female; Humans; Pregnancy; Valproic Acid | 1982 |
Benzodiazepine amplification of valproate teratogenic effects in children of mothers with absence epilepsy.
Topics: Abnormalities, Drug-Induced; Adult; Benzodiazepines; Brain; Child; Child, Preschool; Developmental D | 1993 |
Pharmacokinetic determinants of embryotoxicity in rats associated with organic acids.
Topics: Abnormalities, Drug-Induced; Acids; Administration, Oral; Animals; Caproates; Caprylates; Dose-Respo | 1994 |
Fetal valproate syndrome with reduction deformity of limb.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Arm; Face; Female; Humans; Infant, Newborn; Va | 1995 |
Prevention of neural tube defects.
Topics: Abnormalities, Drug-Induced; Carbamazepine; Female; Folic Acid; Humans; Neural Tube Defects; Pregnan | 1994 |
Aplasia cutis congenita of the scalp in an infant exposed to valproic acid in utero.
Topics: Abnormalities, Drug-Induced; Adult; Causality; Epilepsy; Female; Humans; Infant, Newborn; Male; Preg | 1994 |
Evaluation of the rat embryo culture system as a predictive test for human teratogens.
Topics: Abnormalities, Drug-Induced; Animals; Captopril; Diphenhydramine; DNA; Embryo, Mammalian; False Nega | 1994 |
Radial ray aplasia in utero: a prenatal finding associated with valproic acid exposure.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Carbamazepine; Epilepsy, Absence; Female; Huma | 1994 |
Pregnancy, epilepsy, management and outcome: a 10-year perspective.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Birth Weight; Carbamazepine; Cohort Studies; Drug Ther | 1993 |
Teratogenicity of antiepileptic drugs and drug specific malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Drug | 1993 |
Preaxial ray reduction defects as part of valproic acid embryofetopathy.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Abortion, Therapeutic; Adolescent; Adult; Extr | 1993 |
[Severe bone malformations in fetal valproic acid disease].
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Bone and Bones; Face; Heart Defects, Congenita | 1993 |
Fetal valproate syndrome.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Anticonvulsants; Epilepsy; Face; Female; Human | 1995 |
Pantothenic acid decreases valproic acid-induced neural tube defects in mice (I).
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Bone and Bones; Embryo, Mammalian; Eyelids; F | 1995 |
Teratogenic effects of sodium valproate in mice and rats at midgestation and at term.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Bone and Bones; Brain; Embryonic and Fetal De | 1996 |
Valproic acid-induced somite teratogenesis in the chick embryo: relationship with Pax-1 gene expression.
Topics: Abnormalities, Drug-Induced; Animals; Base Sequence; Bone and Bones; Chick Embryo; DNA-Binding Prote | 1996 |
[Embryofetopathy due to valproate: a pathology only little known. Apropos of 4 cases].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Child, Preschool; Cleft Lip; Epilepsy; Face; Female; F | 1996 |
Effects of the antiepileptic drug valproic acid on the development of the axolotl (Ambystoma mexicanum): histological investigations.
Topics: Abnormalities, Drug-Induced; Ambystoma; Animals; Anticonvulsants; Central Nervous System; Dose-Respo | 1996 |
Valproate-induced developmental modifications maybe partially prevented by coadministration of folinic acid and S-adenosylmethionine.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Bone and Bones; Female; Fetus; Leucovorin; Li | 1996 |
A risk assessment of topical tretinoin as a potential human developmental toxin based on animal and comparative human data.
Topics: Abnormalities, Drug-Induced; Administration, Topical; Animals; Female; Humans; Isotretinoin; Keratol | 1997 |
Correlation of in vitro anti-proliferative potential with in vivo teratogenicity in a series of valproate analogues.
Topics: Abnormalities, Drug-Induced; Animals; Cell Differentiation; Cell Division; Clone Cells; Mice; Struct | 1997 |
[Embryo-fetopathy due to valproate].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Central Nervous System; Female; Fetal Diseases; Humans | 1997 |
Effect of multifactorial genetic liability to exencephaly on the teratogenic effect of valproic acid in mice.
Topics: Abnormalities, Drug-Induced; Animals; Brain; Disease Susceptibility; Female; Fetal Death; Mice; Mice | 1997 |
Stereoselective dysmorphogenicity of the enantiomers of the valproic acid analogue 2-N-propyl-4-pentynoic acid (4-yn-VPA): cross-species evaluation in whole embryo culture.
Topics: Abnormalities, Drug-Induced; Animals; Embryonic and Fetal Development; Fatty Acids, Unsaturated; Fem | 1997 |
Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid.
Topics: Abnormalities, Drug-Induced; Amides; Animals; Anticonvulsants; Body Weight; Embryo, Mammalian; Femal | 1998 |
Teratogenic effects of antiepileptic drugs: what do we advise patients?
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Patient Advoc | 1997 |
[Prenatal ultrasonographic diagnosis in the epileptic mother on valproic acid. Retrospective study of 161 cases in the central eastern France register of congenital malformations].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; France; Humans; Population Surveilla | 1998 |
VPA-induced neural tube defects in mice. I. Altered metabolism of sulfur amino acids and glutathione.
Topics: Abnormalities, Drug-Induced; Amino Acids; Animals; Anticonvulsants; Female; Folic Acid; Glutathione; | 1998 |
Anomalous right pulmonary artery origins in association with the fetal valproate syndrome.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Child, Preschool; Female; Humans; Infant; Male; Pregna | 1999 |
Case-control studies using only malformed infants: are we interpreting the results correctly?
Topics: Abnormalities, Drug-Induced; Case-Control Studies; Congenital Abnormalities; Data Interpretation, St | 1999 |
Failure of periconceptual folic acid to prevent a neural tube defect in the offspring of a mother taking sodium valproate.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Epilepsy, Generalized; Female; Folic Acid; Huma | 1999 |
Malformations in offspring of women with epilepsy: a prospective study.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Comorbidity; Congenital Abnormalities; | 1999 |
[A case of fetal valproate syndrome with intractable wheezing due to submucosal tumor below the vocal cord].
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Fatal Outcome; Female; Humans; Infant; Infant, | 1999 |
A mouse model for valproate teratogenicity: parental effects, homeotic transformations, and altered HOX expression.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Animals; Anticonvulsants; Carcinoma, Embryonal | 2000 |
Blepharoptosis and central nervous system abnormalities in combined valproate and hydantoin embryopathy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Blepharoptosis; Brain; Drug Therapy, Combinatio | 2000 |
Post-axial limb defects with maternal sodium valproate exposure.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Female; Humans; Infant; Limb Deformities, Congenital; | 2000 |
A clinical study of 57 children with fetal anticonvulsant syndromes.
Topics: Abnormalities, Drug-Induced; Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Ep | 2000 |
Developmental toxicity of valproic acid during embryonic chick vertebral chondrogenesis.
Topics: Abnormalities, Drug-Induced; Age Factors; Aggrecans; Animals; Cell Survival; Chick Embryo; Chondroge | 2000 |
Population based, prospective study of the care of women with epilepsy in pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Epilepsy; Female; Fetal Death; Guidelin | 2000 |
Nonspecific stimulation of the maternal immune system. I. Effects On teratogen-induced fetal malformations.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adjuvants, Immunologic; Animals; BCG Vaccine; | 2000 |
Valproate and other anticonvulsants for psychiatric disorders.
Topics: Abnormalities, Drug-Induced; Acetates; Adult; Amines; Anti-Anxiety Agents; Anticonvulsants; Bipolar | 2000 |
The teratogenicity of anticonvulsant drugs.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Case-Control Studies; Congenital Abnorm | 2001 |
Microlissencephaly with cardiac, spinal and urogenital defects.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Anticonvulsants; Brain; Fetal Diseases; Heart | 2001 |
Selection bias in Teratology Information Service pregnancy outcome studies.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; California; Carbamazepine; Drug Information Ser | 2001 |
Septo-optic dysplasia as a manifestation of valproic acid embryopathy.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adolescent; Antimanic Agents; Child, Preschool | 2001 |
[The dangers of valproate in women].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Cholesterol, HDL; Epilepsy; Female; Humans; Hyperandro | 1998 |
Fatal cardiac malformation in fetal valproate syndrome.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Epilepsy; Fatal Outcome; Female; Heart Defects, | 2001 |
'Foetal valproate syndrome and autism: additional evidence of an association'.
Topics: Abnormalities, Drug-Induced; Autistic Disorder; Child; Epilepsy, Generalized; Female; Humans; Male; | 2001 |
[Metopic craniosynostosis, probable effect of intrauterine exposure to maternal valproate treatment].
Topics: Abnormalities, Drug-Induced; Craniosynostoses; Diseases in Twins; Epilepsy, Generalized; Female; Hum | 2001 |
[Teratogenic action of antiepileptic drug: 2-propylpentanoic acid-effects on rat and hamster embryos cultured in vitro].
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Cricetinae; Dose-Response Relationship, Drug; | 2001 |
Ophthalmic findings in fetal anticonvulsant syndrome(s).
Topics: Abnormalities, Drug-Induced; Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Ep | 2002 |
Long-term use of the major anticonvulsant drugs.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Drug Interactions; Epilepsy; Ethosuximi | 1978 |
Methotrexate increases valproic acid-induced developmental toxicity, in particular neural tube defects in mice.
Topics: Abnormalities, Drug-Induced; Animals; Drug Synergism; Encephalocele; Female; Folic Acid; Methotrexat | 1992 |
Valproic acid induced abnormal development of the central nervous system of three species of amphibians: implications for neural tube defects and alternative experimental systems.
Topics: Abnormalities, Drug-Induced; Ambystoma mexicanum; Amphibians; Animals; Central Nervous System; Neura | 1992 |
Valproic acid-induced spina bifida: a mouse model.
Topics: Abnormalities, Drug-Induced; Animals; Disease Models, Animal; Female; Mice; Mice, Inbred Strains; Pr | 1992 |
Preaxial polydactyly in the fetal valproate syndrome.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Face; Female; Fingers; Humans; Infant, Newborn | 1992 |
Pharmacokinetics of valproate and carbamazepine.
Topics: Abnormalities, Drug-Induced; Animals; Carbamazepine; Humans; Intestinal Absorption; Protein Binding; | 1992 |
Antiepileptics and the development of congenital anomalies.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Apgar Score; Birth Weight; Carbamazepine; Epilepsy; Fe | 1992 |
Epilepsy, antiepileptic drugs, and malformations in children of women with epilepsy: a French prospective cohort study.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Cohort Studies; Epilepsy; Female; Humans; Odds | 1992 |
Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Cohort Studies; Drug Prescriptions; Epi | 1992 |
Effect of supplementation with folinic acid, vitamin B6, and vitamin B12 on valproic acid-induced teratogenesis in mice.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Animals; Drug Interactions; Embryo, Mammalian; | 1992 |
Joint action of t-retinoic and valproic acids on Xenopus embryo development.
Topics: Abnormalities, Drug-Induced; Animals; Drug Synergism; Embryo, Nonmammalian; Female; Male; Tretinoin; | 1991 |
[The course of pregnancy and teratogenicity of antiepileptic agents in 66 patients with epilepsy].
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Carbamazepine; Drug Therapy, Combin | 1991 |
Additive incidence of developmental malformation for Xenopus embryos exposed to a mixture of ten aliphatic carboxylic acids.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Animals; Butyrates; Butyric Acid; Caproates; C | 1991 |
The effect of administration time on malformations induced by three anticonvulsant agents in C57BL/6J mice with emphasis on forelimb ectrodactyly.
Topics: Abnormalities, Drug-Induced; Animals; Anophthalmos; Anticonvulsants; Dimethadione; Facial Bones; Fem | 1991 |
Diurnal variation of folate concentrations in mouse embryo and plasma: the protective effect of folinic acid on valproic-acid-induced teratogenicity is time dependent.
Topics: Abnormalities, Drug-Induced; Animals; Chromatography, High Pressure Liquid; Circadian Rhythm; Decidu | 1991 |
[Effects of antiepileptic drugs on delivery and early childhood--comparison among mono-therapies of valproic acid, phenytoin, carbamazepine and phenobarbital].
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Birth Weight; Carbamazepine; Embryonic and Feta | 1991 |
The fetal valproate syndrome.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Child, Preschool; Face; Female; Humans; Male; | 1991 |
[Congenital duodenal stenosis and valproic fetal disease].
Topics: Abnormalities, Drug-Induced; Constriction, Pathologic; Duodenal Diseases; Humans; Infant, Newborn; M | 1991 |
Initial evaluation of developmental malformation as an end point in mixture toxicity hazard assessment for aquatic vertebrates.
Topics: Abnormalities, Drug-Induced; Aminopropionitrile; Animals; Butyrates; Embryo, Nonmammalian; Isoniazid | 1991 |
On the use of anticonvulsants for manic depression during pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Bipolar Disorder; Carbamazepine; Female; Humans; Infan | 1990 |
Proximal phocomelia and radial ray aplasia in fetal valproic syndrome.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Bone and Bones; Ectromelia; Female; Humans; In | 1990 |
Induction of postaxial forelimb ectrodactyly with anticonvulsant agents in A/J mice.
Topics: Abnormalities, Drug-Induced; Animals; Birth Weight; Dimethadione; Female; Fetal Death; Fetal Resorpt | 1990 |
Teratogenic effects on the neuroepithelium of the CD-1 mouse embryo exposed in utero to sodium valproate.
Topics: Abnormalities, Drug-Induced; Animals; Brain; Electrophoresis, Gel, Two-Dimensional; Epithelium; Fema | 1990 |
Neocerebellar hypoplasia in a neonate following intra-uterine exposure to anticonvulsants.
Topics: Abnormalities, Drug-Induced; Cerebellum; Drug Therapy, Combination; Epilepsy; Female; Humans; Nerve | 1990 |
Clinical manifestation of prenatal exposure to valproic acid using case reports and epidemiologic information.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Case-Control Studies; Face; Female; Humans; Infant, Ne | 1990 |
Depakine-induced embryopathy.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Bone and Bones; Humans; Infant, Newborn; Radio | 1990 |
[Effects of Shosaiko-to-go-keishikashakuyaku-to (TJ-960) on the valproic acid induced anomalies of rat fetuses].
Topics: Abnormalities, Drug-Induced; Animals; Drug Interactions; Drugs, Chinese Herbal; Female; Fetus; Male; | 1990 |
Teratogenic effects of sodium valproate in the Jcl: ICR mouse fetus.
Topics: Abnormalities, Drug-Induced; Animals; Female; Fetus; Gestational Age; Heart Defects, Congenital; Hum | 1990 |
[The first case of a child born with fetal valproic acid syndrome in Hungary].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Humans; Infant, Newborn; Maternal-Fe | 1989 |
The effect of valproic acid on 65Zn distribution in the pregnant rat.
Topics: Abnormalities, Drug-Induced; Animals; Carrier Proteins; Female; Fetus; Liver; Molecular Weight; Plac | 1989 |
Fetal valproate phenotype is recognisable by mid pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Female; Fetal Diseases; Humans; Meningomyelocele; Phenotype; Pre | 1989 |
Asymmetric synthesis and enantioselective teratogenicity of 2-n-propyl-4-pentenoic acid (4-en-VPA), an active metabolite of the anticonvulsant drug, valproic acid.
Topics: Abnormalities, Drug-Induced; Animals; Fatty Acids, Monounsaturated; Female; Mice; Neural Tube Defect | 1989 |
Epilepsy in women of childbearing age.
Topics: Abnormalities, Drug-Induced; Adult; Carbamazepine; Epilepsy; Female; Humans; Pregnancy; Pregnancy Co | 1989 |
[Valproate induced fetopathy and somatic and psychomotor development].
Topics: Abnormalities, Drug-Induced; Epilepsy; Female; Fetal Diseases; Humans; Maternal-Fetal Exchange; Preg | 1989 |
Valproate, spina bifida, and birth defect registries.
Topics: Abnormalities, Drug-Induced; Female; Humans; Infant, Newborn; Ireland; Pregnancy; Registries; Spina | 1989 |
Inhibition of epoxide hydrolase by anticonvulsants and risk of teratogenicity.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Drug Interactions; Epoxide Hydrolases; Female; Humans; | 1989 |
Valpromide/carbamazepine and risk of teratogenicity.
Topics: Abnormalities, Drug-Induced; Animals; Carbamazepine; Drug Therapy, Combination; Epilepsy; Female; Hu | 1985 |
Valproate, spina bifida, and birth defect registries.
Topics: Abnormalities, Drug-Induced; Epilepsy; Female; Humans; Pregnancy; Pregnancy Complications; Registrie | 1988 |
Valproic acid teratogenicity in whole embryo culture is not prevented by zinc supplementation.
Topics: Abnormalities, Drug-Induced; Animals; Embryo, Mammalian; Female; Organ Culture Techniques; Pregnancy | 1986 |
Predicting the human teratogenic potential of the anticonvulsant, valproic acid, from a non-human primate model.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Female; Fetus; Gestational Age; Half-Lif | 1986 |
Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Epilepsy; Female; Fetus; Growth; Humans; Infant, New | 1986 |
Fetal valproate syndrome.
Topics: Abnormalities, Drug-Induced; Face; Humans; Syndrome; Valproic Acid | 1986 |
Pharmacokinetic aspects of drug effects in vitro: effects of serum protein binding on concentration and teratogenicity of valproic acid and 2-en-valproic acid in whole embryos in culture.
Topics: Abnormalities, Drug-Induced; Animals; Blood Proteins; Embryo, Mammalian; Fatty Acids, Monounsaturate | 1986 |
Teratogenesis of calcium valproate in rabbits.
Topics: Abnormalities, Drug-Induced; Animals; Female; Gestational Age; Maternal-Fetal Exchange; Pregnancy; R | 1986 |
[Combination of hydantoins and valproate. Evidence of its teratogenic effect in 4 consecutive gestations].
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Child; Child, Preschool; Drug Therapy, Combina | 1986 |
Species differences in pharmacokinetics and drug teratogenesis.
Topics: Abnormalities, Drug-Induced; Animals; Blood Proteins; Cricetinae; Female; Half-Life; Haplorhini; Hum | 1986 |
Results of in vivo and in vitro studies for assessing prenatal toxicity.
Topics: Abnormalities, Drug-Induced; Acyclovir; Animals; Disinfectants; Embryo, Mammalian; Estrogens; Mice; | 1986 |
Teratogenicity of di(2-ethylhexyl) phthalate, 2-ethylhexanol, 2-ethylhexanoic acid, and valproic acid, and potentiation by caffeine.
Topics: Abnormalities, Drug-Induced; Animals; Caffeine; Caproates; Diethylhexyl Phthalate; Drug Synergism; F | 1987 |
On the ability of birth defects monitoring to detect new teratogens.
Topics: Abnormalities, Drug-Induced; Epidemiologic Methods; Humans; Infant, Newborn; Isotretinoin; Risk; Ter | 1987 |
Teratogenicity and developmental toxicity of valproic acid in rats.
Topics: Abnormalities, Drug-Induced; Animals; Animals, Newborn; Body Weight; Dose-Response Relationship, Dru | 1987 |
Anticonvulsant drugs in monotherapy. Effect on the fetus.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Fe | 1987 |
The management of epilepsy in women of child-bearing age and the Australian experience of valproate in pregnancy.
Topics: Abnormalities, Drug-Induced; Australia; Epilepsy; Female; Humans; Infant, Newborn; Pregnancy; Pregna | 1987 |
Fetal valproate syndrome: is there a recognisable phenotype?
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Epilepsy, Tonic-Clonic; Female; Humans; Infant | 1987 |
The role of ultrasound in the early diagnosis of fetal structural defects following maternal anticonvulsant therapy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Diazepam; Female; Humans; Infant, Newbo | 1988 |
Congenital abnormalities in two sibs exposed to valproic acid in utero.
Topics: Abnormalities, Drug-Induced; Carbamazepine; Child; Child, Preschool; Epilepsy; Female; Humans; Infan | 1988 |
The fetal valproate syndrome.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Female; Fetus; Humans; Infant, Newborn; Pregnancy; Syn | 1988 |
Valproic acid developmental toxicity and pharmacokinetics in the rhesus monkey: an interspecies comparison.
Topics: Abnormalities, Drug-Induced; Animals; Blood Proteins; Female; Fetus; Macaca; Macaca mulatta; Protein | 1988 |
[Neural tube malformations in children of mothers treated with sodium valproate].
Topics: Abnormalities, Drug-Induced; Female; France; Humans; Infant, Newborn; Pregnancy; Risk; Spina Bifida | 1985 |
Valproic acid teratogenicity: demonstration that the biochemical mechanism differs from that of valproate hepatotoxicity.
Topics: Abnormalities, Drug-Induced; Acetyl Coenzyme A; Acyl Coenzyme A; Animals; In Vitro Techniques; Liver | 1985 |
Teratogenic effects of valproate in the CD-1 mouse fetus.
Topics: Abnormalities, Drug-Induced; Animals; Brain; Female; Fetal Diseases; Mice; Mice, Inbred Strains; Pre | 1985 |
Teratogenic potential of valproate.
Topics: Abnormalities, Drug-Induced; Animals; Female; Humans; Maternal-Fetal Exchange; Pregnancy; Valproic A | 1985 |
Maternal epilepsy and birth defects: a case-control study in the Italian Multicentric Registry of Birth Defects (IPIMC).
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Chromosome Aberrations; Chromosome Disorders; Chromoso | 1985 |